Pyrroloisoquinoline compounds and their uses in therapy

By providing a pyrroloisoquinoline compound of formula (I) to inhibit MK2 activity, the problem of the ineffectiveness of existing treatments is solved, achieving effective treatment of inflammatory disorders, relieving symptoms and improving quality of life.

CN123124971APending Publication Date: 2026-11-17MIKE PUENTE THERAPEUTICS INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202480074835.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-01
Filing Date
2024-10-31
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing treatments for inflammatory disorders are ineffective or have undesirable adverse effects in a significant proportion of patients, necessitating new therapies to treat inflammatory disorders mediated by mitogen-activated protein kinase-activated protein kinase 2 (MK2).

Method used

Pyrroloisoquinoline compounds of formula (I) and their pharmaceutically acceptable salts are provided for inhibiting the activity of MK2, and for administration to patients via pharmaceutical compositions to treat diseases or conditions mediated by MK2.

Benefits of technology

It effectively inhibits MK2 activity, reduces inflammatory response, alleviates symptoms of inflammatory disorders, slows disease progression, and improves patients' quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124971A_ABST
    Figure CN123124971A_ABST
Patent Text Reader

Abstract

This document provides compounds of formula (I): (I) or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, wherein L, R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 15 R 16 X, p, and q are defined elsewhere in this document. Methods for preparing compounds of formula (I) are also provided. Methods for inhibiting MK2 and for treating MK2-mediated diseases or conditions in individuals in need are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-references to related applications

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 595,193, filed November 1, 2023, which is hereby incorporated herein by reference in its entirety. Technical Field

[0002] The present invention relates generally to pyrroloisoquinoline compounds, pharmaceutical compositions, kits comprising said pyrroloisoquinoline compounds and said pharmaceutical compositions, their use for inhibiting mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MAPKAPK2, MK2) and their use in treating diseases or conditions (e.g., inflammatory disorders). Background Technology

[0003] Inflammatory disorders affect a large number of patients and typically involve a patient's biological response to a stimulus that causes the immune system to attack the body's own cells or tissues. This can lead to abnormal inflammation and cause chronic pain, redness, swelling, stiffness, and / or damage to normal tissues. Inflammatory disorders can be characterized by whether they are acute or chronic. Common inflammatory disorders that affect a large number of patients each year include inflammatory bowel disease, asthma, rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

[0004] Common treatments for inflammatory disorders currently available include nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, or naproxen, corticosteroids (such as prednisone), and various biologics such as abatacept, adalimumab, cetrus, etanercept, infliximab, golimumab, rituximab, and tocilizumab. Compounds with inhibitory activity against mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) have also been reported in the literature for use in the treatment of certain inflammatory disorders. See, for example, U.S. Patent Application Publication No. 2016 / 0075720, U.S. Patent Application Publication No. 2022 / 0251105, U.S. Patent Application Publication No. 2023 / 0255979, and International Patent Publications WO 2020 / 236636 and WO 2022 / 020562.

[0005] Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) has been reported in the literature to mediate various p38 MAPK-dependent cellular responses. See, for example, U.S. Patent Application 2016 / 0075720. MK2 has also been reported as an important intracellular regulator of cytokine production, including cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interferon-γ (IFNg), each involved in several acute and chronic inflammatory diseases. MK2 is also involved in the regulation of heart failure, ischemic brain injury, stress resistance, and TNF-α production. See, for example, Deak et al., EMBO.17:4426-4441 (1998); Shi et al., Biol. Chem . 383:1519-1536 (2002); Staklatvala., Curr. Opin. Pharmacol 4:372-377 (2004); and Shiroto et al., J. Mol. Cardiol 38:93-97 (2005).

[0006] Existing treatments for inflammatory disorders may be ineffective and / or have undesirable adverse effects in a significant proportion of patients. Therefore, new therapies are needed to treat inflammatory disorders. Summary of the Invention

[0007] In one respect, this paper provides compounds of formula (I), (I), Or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, wherein L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R) 10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further surrounded by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R 13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 alkenyl, C 1-4 alkynyl group, C 3-4 cycloalkyl or 3-8 membered heterocyclic groups; Wherein C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 1-4 alkenyl or the C1-4 The alkynyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl or the 3-8 membered heterocyclic group is optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR 14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14 (R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 -N(R) 14 (R) 14 ) or 3-8 membered heterocyclic groups, among which The 3-8 membered heterocyclic group is optionally halogenated, C 1-4 Alkyl or C 1-4 Halogenated alkyl substitution; R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-6 cycloalkyl; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18 It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups. The condition is that when L is -O-, R 1 -R 6 Each of them is H, R 7 It is 2-chloropyrimidin-4-yl, X is CF. It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

[0008] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R)10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further surrounded by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R 13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and R. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl; Wherein C 1-4 alkyl or the C 1-4 The haloalkyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14 (R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 or -N(R) 14 (R) 14 ); R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl groups; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups. The condition is that when L is -O-, R 1 -R 6 Each of them is H, R 7 It is 2-chloropyrimidin-4-yl, X is CF. It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

[0009] Any embodiment of a compound of formula (I) provided herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is applicable where applicable to any other formula detailed herein, as if each embodiment were specifically and separately listed. Therefore, it should be understood and described that each embodiment of a compound of formula (I) provided herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing (e.g., with L, R) 1 R 2 R 2a R 3 R 4 R 4a R 5 R 6 R 7 R 8 R 9 R 9a R 9b R 9c R 10 R 10a R 10b R 11 R 12 R 13 R 14 R 15 R 16The embodiments related to n, p, q, and X are all applicable to formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), or their stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, as if each embodiment were specifically and individually listed. It should also be understood and described that all such embodiments are applicable to any of the pharmaceutical compositions, methods, kits, uses, or other aspects detailed herein.

[0010] In one aspect, a pharmaceutical composition is provided comprising a compound of formula (I) or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0011] In one aspect, a method for treating a disease or condition mediated by MK2 is provided, the method comprising administering to a subject in need a compound of formula (I) or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0012] In one aspect, this document provides a method for inhibiting MK2 activity, the method comprising contacting MK2 with an effective amount of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0013] In one aspect, this document provides a method for covalently modifying MK2, the method comprising contacting MK2 with an effective amount of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0014] In one aspect, this document provides a covalently modified MK2 formed by contacting MK2 with an effective amount of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0015] In one aspect, this document provides a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, for use in the treatment of diseases or conditions mediated by MK2. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0016] In one aspect, this document provides the use of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease or condition mediated by MK2. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0017] In one aspect, this document provides a kit comprising (i) a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating MK2-mediated diseases or conditions in individuals of need. In some embodiments, this aspect may employ a compound of any one of formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), and (Io), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43, and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0018] All pharmaceutical compositions, methods, kits, uses, or other aspects described herein with respect to formula (I), or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, are also described herein and cover any of the other formulas detailed herein (e.g., formulas (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, and compounds selected from compounds 1-32, 34-43, and 45-189 of Table 1, as if each embodiment were specifically and separately listed. Detailed Implementation

[0019] "Individual" refers to a mammal and includes both humans and non-human mammals. Examples of individuals include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cattle, and humans. In some implementations, an individual refers to a human.

[0020] As used in this article, “about” includes and describes the parameter or value itself. For example, “about X” includes and describes X itself.

[0021] "Treatment" or "treating" is a method used to achieve a beneficial or desired outcome, including clinical outcomes. Beneficial or desired outcomes may include one or more of the following: reducing one or more symptoms caused by a disease or condition; reducing the severity of a disease or condition; slowing or preventing the development of one or more symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or delaying the worsening or progression of a disease or condition); and alleviating a disease, for example by causing the disappearance of clinical symptoms (e.g., improving the disease state, enhancing the effect of another medication, delaying the progression of the disease, improving quality of life, and / or prolonging survival).

[0022] As used herein, “delay” the development of a disease or disorder means postponing, hindering, slowing, delaying, stabilizing, and / or slowing the progression of the disease or disorder. This delay may vary in length depending on the individual’s medical history and / or treatment received. As will be apparent to those skilled in the art, a sufficient or significant delay can effectively encompass prevention, as the individual does not develop the disease or disorder.

[0023] As used herein, the term "therapeutic effective amount" or "effective amount" means an amount sufficient to produce a therapeutic effect when a compound of this disclosure or a pharmaceutically acceptable salt thereof is administered to an individual. As understood in the art, an effective amount can be one or more doses, for example, a single dose or multiple doses may be required to achieve the desired therapeutic endpoint. An "effective amount" may be considered in the context of administration of one or more therapeutic agents, and a single agent may be considered to have been administered in an effective amount if a desired or beneficial result is achieved or realized in combination with one or more other agents.

[0024] As used in this article, “unit dosage form” refers to a physically discrete unit suitable as a unit dose, each unit containing a predetermined amount of active ingredient or compound in a pharmaceutically acceptable carrier.

[0025] As used herein, “pharmaceutically acceptable” means a substance that is not biologically or otherwise undesirable, for example, a substance that can be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.

[0026] As used herein, the term "alkyl" refers to a non-branched or branched saturated monovalent hydrocarbon chain. As used herein, alkyl groups have 1–20 carbon atoms (i.e., C64-C64). 1-20 Alkyl groups), 1-16 carbons (i.e., C16) 1-16 Alkyl groups), 1-12 carbons (i.e., C46) 1-12 Alkyl groups), 1-10 carbons (i.e., C46) 1-10 Alkyl groups), 1-8 carbons (i.e., C46) 1-8 Alkyl groups), 1-6 carbons (i.e., C46) 1-6Alkyl groups), 1-4 carbons (i.e., C46) 1-4 Alkyl groups or 1-3 carbons (i.e., C46) 1-3 Alkyl groups). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, and alkyl groups. different propyl just Butyl, Zhong Butyl, different Butyl, Uncle Butyl, pentyl, 2-pentyl different pentyl, new Pentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue with a specific number of carbon atoms is named by its chemical name or molecular formula, it may include all positional isomers having that number of carbon atoms; for example, "butyl" covers n-butyl, sec-butyl, isobutyl, and tert-butyl; "propyl" includes n-propyl and isopropyl. Certain commonly used alternative names may be used, which will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkyl", may be called an "alkylene".

[0027] As used herein, the term "alkenyl" refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon double bond. As used herein, alkenyl groups have 2–20 carbons (i.e., C60 ... 2-20 alkenyl), 2-16 carbons (i.e., C10), 2-16 alkenyl), 2-12 carbons (i.e., C10), 2-12 alkenyl), 2-10 carbons (i.e., C10), 2-10 alkenyl), 2-8 carbons (i.e., C10), 2-8 alkenyl), 2-6 carbons (i.e., C10), 2-6 alkenyl), 2-4 carbons (i.e., C10), 2-4 Alkenyl) or 2-3 carbons (i.e., C) 2-3 Alkenyl groups. Examples of alkenyl groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1,2-butadienyl, and 1,3-butadienyl. When an alkenyl residue having a specific number of carbon atoms is named by its chemical name or molecular formula, all positional isomers having that number of carbon atoms may be included; for example, "propenyl" encompasses both 1-propenyl and 2-propenyl. Certain commonly used alternative names may be used, which will be understood by those skilled in the art. For example, divalent groups, such as divalent "alkenyl," may be referred to as "alkenylidene."

[0028] As used herein, the term "alkynyl" refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon triple bond. As used herein, an alkynyl group has 2–20 carbons (i.e., C60 ... 2-20 alkynyl group), 2-16 carbons (i.e., C16-C26) 2-16 alkynyl group), 2-12 carbons (i.e., C12-C22) 2-12 alkynyl group), 2-10 carbons (i.e., C10-C20) 2-10alkynyl group), 2-8 carbons (i.e., C10-C20) 2-8 alkynyl group), 2-6 carbons (i.e., C10-C20) 2-6 alkynyl group), 2-4 carbons (i.e., C10-C20) 2-4 (alkynyl group) or 2-3 carbons (i.e., C10) 2-3 (Alynyl group). Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl-1-alkynyl, propynyl-2-alkynyl, butynyl-1-alkynyl, butynyl-2-alkynyl, and butynyl-3-alkynyl. When an alkynyl residue having a specific number of carbon atoms is named by its chemical name or molecular formula, it may include all positional isomers having that number of carbon atoms; for example, "propynyl" includes both propynyl-1-alkynyl and propynyl-2-alkynyl. Certain commonly used alternative names may be used, which will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkynyl," may be called an "alkynylene".

[0029] As used herein, the term "alkoxy" refers to the -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexyloxy, and 1,2-dimethylbutoxy.

[0030] As used herein, the term "aryl" refers to a fully unsaturated carbocyclic moiety. The term "aryl" encompasses both monocyclic and polycyclic fused-ring moieties. As used herein, aryl encompasses moieties containing, for example, 6 to 20 cyclic carbon atoms (i.e., C24 ... 6-20 aryl), 6 to 16 cyclic carbon atoms (i.e., C 6-16 aryl), 6 to 12 cyclic carbon atoms (i.e., C 6-12 aryl group or 6 to 10 cyclic carbon atoms (i.e., C46, ​​C56, C6 ... 6-10 The ring moiety of an aryl group. Examples of aryl moiety include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthracene.

[0031] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated carbocyclic moiety. The term "cycloalkyl" encompasses both monocyclic and polycyclic moieties, wherein the polycyclic moiety may be fused, branched, or spirocyclic. Cycloalkyl includes cycloalkenyl groups, wherein the cyclic moiety contains at least one cyclic double bond. Cycloalkyl includes any polycyclic carbocyclic moiety containing at least one non-aromatic ring, regardless of its attachment point to the remainder of the molecule. As used herein, cycloalkyl includes, for example, a moiety containing 3 to 20 cyclic carbon atoms (i.e., C64 ... 3-20 cycloalkyl groups), 3 to 16 cyclic carbon atoms (i.e., C164 ... 3-16 cycloalkyl groups), 3 to 12 cyclic carbon atoms (i.e., C12C ... 3-12 cycloalkyl groups), 3 to 10 cyclic carbon atoms (i.e., C10, C20, C30, C40, C50, C60, C7 ... 3-10 cycloalkyl groups), 3 to 8 cyclic carbon atoms (i.e., C1646-C264 ... 3-8 cycloalkyl groups), 3 to 6 cyclic carbon atoms (i.e., C164-C ... 3-6cycloalkyl groups or 3 to 5 cyclic carbon atoms (i.e., C164, C264, C364, C464, C5 ... 3-5 The cycloalkyl group is a ring. Monocyclic cycloalkyl ring moiety includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclic [2.2.1]heptyl, bicyclic [2.2.2]octyl, adamantyl, norbornyl, decahydronaphthyl, 7,7-dimethyl-bicyclic [2.2.1]heptyl, etc. In addition, cycloalkyl also includes spirocycloalkyl ring moiety, such as spiro[2.5]octyl, spiro[4.5]decyl, or spiro[5.5]undecyl.

[0032] As used herein, the term "halogenated" refers to an atom occupying Group VIIA of the periodic table and includes fluorine (fluorinated), chlorine (chloroinated), bromine (brominated), and iodine (iodinated). Furthermore, the term "halogenated alkyl" is intended to include both monohalogenated and polyhalogenated alkyl groups. For example, the term "C" 1-4 "Haloalkyl" is intended to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, difluoromethyl, etc. The term "haloalkenyl" is intended to include both monohaloalkenyl and polyhaloalkenyl groups. For example, the term "C" 1-4 The term "haloalkenyl" is intended to include 4,4,4-trifluorobut-1-en-1-yl, 1-fluoroprop-1-en-1-yl, 1,3,3-trichloroprop-1-en-1-yl, etc. The term "haloalkynyl" is intended to include both monohaloalkynyl and polyhaloalkynyl groups. For example, the term "C 1-4 "Halogenated alkyne" is intended to include fluoroacetylene, 1,1-difluoroprop-2-yn-1-yl, 1-chloro-1-fluorobut-2-yn-1-yl, etc.

[0033] As used herein, the term "heteroaryl" refers to an aromatic (fully unsaturated) ring moiety containing one or more cyclic heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heteroaryl" includes both monocyclic and polycyclic fused-ring moieties. Heteroaryls as used herein include, for example, 5 to 20 ring atoms (i.e., 5-20-membered heteroaryls), 5 to 16 ring atoms (i.e., 5-16-membered heteroaryls), 5 to 12 ring atoms (i.e., 5-12-membered heteroaryls), 5 to 10 ring atoms (i.e., 5-10-membered heteroaryls), 5 to 8 ring atoms (i.e., 5-8-membered heteroaryls), or 5 to 6 ring atoms (i.e., 5-6-membered heteroaryls). Any monocyclic or polycyclic aromatic ring moiety containing one or more cyclic heteroatoms is considered a heteroaryl, regardless of its attachment point to the remainder of the molecule (i.e., the heteroaryl moiety can be attached to the remainder of the molecule by any cyclic carbon or any cyclic heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, and pyridazinyl.

[0034] As used herein, the term "heterocyclic group" refers to a saturated or partially unsaturated cyclic moiety encompassing one or more cyclic heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heterocyclic group" includes both monocyclic and polycyclic moieties, wherein the polycyclic moieties may be fused, bridged, or spirocyclic. Any non-aromatic monocyclic or polycyclic moieties containing at least one cyclic heteroatom are considered heterocyclic groups, regardless of their connection points to the remainder of the molecule (i.e., the heterocyclic group moieties may be connected to the remainder of the molecule via any cyclic carbon or any cyclic heteroatom of the heterocyclic group moieties). Furthermore, the term "heterocyclic group" is intended to cover any polycyclic moieties containing at least one cyclic heteroatom, wherein said polycyclic moieties contain at least one non-aromatic ring, regardless of their connection points to the remainder of the molecule. As used herein, heterocyclic groups comprise, for example, 3 to 20 ring atoms (i.e., 3-20 membered heterocyclic groups), 3 to 16 ring atoms (i.e., 3-16 membered heterocyclic groups), 3 to 12 ring atoms (i.e., 3-12 membered heterocyclic groups), 3 to 10 ring atoms (i.e., 3-10 membered heterocyclic groups), 3 to 8 ring atoms (i.e., 3-8 membered heterocyclic groups), 3 to 6 ring atoms (i.e., 3-6 membered heterocyclic groups), 3 to 5 ring atoms (i.e., 3-5 membered heterocyclic groups), 5 to 8 ring atoms (i.e., 5-8 membered heterocyclic groups), or 5 to 6 ring atoms (i.e., 5-6 membered heterocyclic groups). Examples of heterocyclic groups include, for example, aziridine, piperidinyl, pyrrolidine, pyrazolyl, thiazolyl, tetrahydrofuranyl, and tetrahydropyranyl. Examples of spiroheterocyclic rings include, but are not limited to, bicyclic and tricyclic systems, such as oxabicyclo[2.2.2]octyl, 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.4]octyl, and 6-oxa-1-azaspiro[3.3]heptyl. Examples of fused heterocyclic rings include, but are not limited to, 5,6,7,8-tetrahydropyridino[4,3-d]pyrimidinyl, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidinyl, 5,7-dihydrofurano[3,4-d]pyrimidinyl, and 5,7-dihydrothieno[3,4-d]pyrimidinyl, wherein the heterocyclic group can be bonded via any ring of the fused system.

[0035] As used in this article, the term "oxo" refers to the =O portion.

[0036] As used herein, the terms “optional” or “optionally” mean that the event or situation described below may or may not occur, and the description includes instances where the event or situation occurs and instances where it does not occur. Thus, the term “optionally substituted” means that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on a specified atom or part or group may or may not be substituted with atoms or parts or groups other than hydrogen. By way of example only and not limitation, the phrase “methyl group optionally substituted with one or more chlorine atoms” covers the -CH3, -CH2Cl, -CHCl2, and -CCl3 moieties.

[0037] It should be understood that the aspects and implementation schemes described herein as "comprising" include implementation schemes that are "composed of" and "substantially composed of".

[0038] As used herein, the term "pharmaceutically acceptable salt" for a given compound means a salt that retains the biological efficacy and properties of the given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salt" includes, for example, salts formed with inorganic acids and salts formed with organic acids. Furthermore, if the compound described herein is obtained as an acid addition salt, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, the addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with acid, following the conventional procedure for preparing acid addition salts from basic compounds. See, for example, Handbook of Pharmaceutical Salts Properties, Selection, and Use [Reference to John Wiley & Sons (2008), International Union of Pure and Applied Chemistry, which is incorporated herein by reference in its entirety.] Those skilled in the art will recognize the various synthetic methods that can be used to prepare non-toxic, pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Salts derived from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, trifluoroacetic acid, etc. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include (by way of example only) sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include (by way of example only) isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, etc.

[0039] Isotopically labeled forms of the compounds described herein can be prepared. The isotopically labeled compounds have the structures described herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, respectively, for example... 2 H, 3 H, 11 C 13 C 14 C13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 36 Cl、 123 I and 125 I. In some embodiments, compounds of formula (I) are provided, wherein one or more hydrogen atoms are replaced by deuterium or tritium.

[0040] Some of the compounds described herein can exist as tautomers. These tautomers exist in equilibrium with each other. For example, amide-containing compounds can exist in equilibrium with imide acid tautomers. Regardless of which tautomer is exhibited and regardless of the equilibrium nature between the tautomers, those skilled in the art will understand that the compounds disclosed herein comprise both amide and imide acid tautomers. Thus, for example, amide-containing compounds are understood to include their imide acid tautomers. Similarly, imide acid-containing compounds are understood to include their amide tautomers.

[0041] This article also provides prodrugs of the compounds described herein, or pharmaceutically acceptable salts thereof. A prodrug is a compound that can be administered to an individual and release, in vivo, the parent drug compound described herein. It should be understood that prodrugs can be prepared by modifying functional groups on the parent drug compound such that the modification is cleaved in vitro or in vivo to release the parent drug compound. See, for example, Rautio, J., Kumpulainen, H., Heimbach, T. et al., Prodrugs: design and clinical applications. Nat Rev Drug Discov 7, 255–270 (2008), which is incorporated herein by reference in its entirety.

[0042] The compounds disclosed herein, or pharmaceutically acceptable salts thereof, may contain an asymmetric center and thus may produce enantiomers, diastereomers, and other stereoisomers, which may be defined in terms of absolute stereochemistry as ( R )-or( S (or defined for amino acids as (D)- or (L)-). This disclosure is intended to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), ( R )-and( S(D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques such as chromatography and / or fractional crystallization. Conventional techniques for preparing / separating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of racemic mixtures (or racemic mixtures of salts or derivatives) using, for example, chiral high-performance liquid chromatography (HPLC) and chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other geometrically asymmetric centers, this disclosure is intended to include both E and Z geometric isomers unless otherwise specified. Similarly, cis and trans are used in their conventional sense to describe relative spatial relationships.

[0043] "Stereoisomers" are compounds composed of identical atoms bonded by identical bonds, but with different three-dimensional structures and are not interchangeable. This disclosure considers various stereoisomers or mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose structures are mirror images of each other without overlapping. "Diabeta-isomers" are stereoisomers having at least two asymmetric atoms that are not mirror images of each other.

[0044] Given a structure with enantiomers and / or diastereomers, planar bonds indicate that all stereoisomers of the described structure can exist, for example, .

[0045] In the presence of enantiomers in a given structure, the presence of planar bonds and the asterisk (*) symbol, or wedge-shaped or dashed bonds in the presence of "or 1", indicates that the composition consists of at least 90% by weight of a single isomer with an unknown absolute stereochemistry, for example, or .

[0046] In the case where a given structure having two or more stereocenters exists in enantiomeric and / or diastereomeric forms, the presence of planar bonds and two or more "*" symbols indicates that the composition consists of at least 90% by weight of a single enantiomer or diastereomer having an unknown absolute stereochemistry, for example... .

[0047] In the case where a given structure having two or more stereocenters exists in enantiomeric and / or diastereomeric forms, the presence of dashed or wedge-shaped bonds and two or more "or" signs with the same value indicates that the composition consists of at least 90% by weight of a single isomer having a known relative stereochemistry, for example, .

[0048] In cases where a given structure exists in enantiomeric and / or diastereomeric forms, the composition consists of at least 90% by weight of a single enantiomer or diastereomer, indicated by dashed or wedge bonds, having a known relative or absolute stereochemistry, for example, .

[0049] compound In one respect, this paper provides compounds of formula (I), (I), Or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, wherein L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R) 10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4Halogenated alkyne group, -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further surrounded by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 alkenyl, C 1-4 alkynyl group, C 3-4 cycloalkyl or 3-8 membered heterocyclic groups; Wherein C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 1-4 alkenyl or the C 1-4 The alkynyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl or the 3-8 membered heterocyclic group is optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR 14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14(R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 -N(R) 14 (R) 14 ) or 3-8 membered heterocyclic groups, among which The 3-8 membered heterocyclic group is optionally halogenated, C 1-4 Alkyl or C 1-4 Halogenated alkyl substitution; R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-6 cycloalkyl; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18 It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups. The condition is that when L is -O-, R 1 -R 6 Each of them is H, R7 It is 2-chloropyrimidin-4-yl, X is CF. It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

[0050] In one respect, this paper provides compounds of formula (I): (I), Or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, wherein L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R) 10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -OR10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further surrounded by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and R. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl; Wherein C 1-4 alkyl or the C 1-4 The haloalkyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR 14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14 (R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 or -N(R) 14 (R) 14 ); R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl groups; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18 It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups. The condition is that when L is -O-, R 1 -R 6 Each of them is H, R 7 It is 2-chloropyrimidin-4-yl, X is CF. It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

[0051] In some embodiments of the compound of formula (I), or any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing: R 5 Is it H or C? 1-2 alkyl; R 6 Is it H or C? 1-2 alkyl; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 quinone heteroaryl, among which The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ;and Each R 4a It is C 1-4 alkyl.

[0052] In some embodiments of the compound of formula (I), or any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing: R 5 Is it H or C? 1-2 alkyl; R 6 Is it H or C? 1-2 alkyl; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 quinone heteroaryl, among which The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ;and Each R 4a It is C 1-4 alkyl.

[0053] In some implementations, when L is -O-, R 1 -R 6 Each of them is H, R 7 It is 2-chloropyrimidin-4-yl, X is CF, It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

[0054] In some embodiments, the compound is not 2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7 H -pyrido[3',4':4,5]pyrrolo[2,3- f Isoquinoline-7-one.

[0055] In some embodiments of the compound of formula (I), or any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing: R 5 Is it H or C? 1-2 alkyl; R 6 Is it H or C? 1-2 alkyl; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 quinone heteroaryl, among which The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and R. 14 ;and Each R 4a It is C1-4 alkyl.

[0056] In some embodiments, the compound of formula (I) is the compound of formula (Ia-1): (Ia-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

[0057] In some embodiments, the compound of formula (I) is a compound of formula (Ia-2): (Ia-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

[0058] In some embodiments, the compound of formula (I) is a compound of formula (Ib-1): (Ib-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0059] In some embodiments, the compound of formula (I) is a compound of formula (Ib-2): (Ib-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0060] In some embodiments, the compound of formula (I) is the compound of formula (Ic-1): (Ic-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0061] In some embodiments, the compound of formula (I) is a compound of formula (Ic-2): (Ic-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0062] In some embodiments, the compound of formula (I) is the compound of formula (Id-1): (Id-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0063] In some embodiments, the compound of formula (I) is a compound of formula (Id-2): (Id-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0064] In some embodiments, the compound of formula (I) is the compound of formula (Ie): (Ie), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0065] In some implementations, the compound of formula (I) is the compound of formula (If): (If), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0066] In some embodiments, the compound of formula (I) is the compound of formula (Ig): (Ig), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0067] In some embodiments, the compound of formula (I) is a compound of formula (Ih): (Ih), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0068] In some embodiments, the compound of formula (I) is the same as the compound of formula (Ii): (Ii), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0069] In some embodiments, the compound of formula (I) is the compound of formula (Ij): (Ij), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0070] In some embodiments, the compound of formula (I) is a compound of formula (Ik): (Ik), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0071] In some embodiments, the compound of formula (I) is a compound of formula (Im): (Im), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0072] In some embodiments, the compound of formula (I) is the compound of formula (In): (In), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0073] In some embodiments, the compound of formula (I) is the compound of formula (Io): (Io), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0074] In some embodiments of compounds of formula (I), or any variant or embodiment thereof, or pharmaceutically acceptable salts of any of the foregoing, L is -C(R 17 (R) 18 -, -C(O)-, -O-, -NR 10 -, -S-, -S(O)-, or -S(O)2-. In some implementations, L is -C(R)2-. 17 (R) 18 -, -C(O)-, -NR 10 -, -S-, -S(O)-, or -S(O)2-. In some implementations, L is -C(R)2-. 17 (R) 18 -, -C(O)-, -O-, or -NR 10 - In some implementations, L is -C(R) 17 (R) 18 -, -C(O)- or -NR 10 - In some implementations, L is -CH2-, -CHF-, -CF2-, -CH(CH3)-, -C(CH3)2-, -C(CH3)(CF3)-, -C(OH)(H)-, -C(OH)(CH3)-, -C(OH)(CF3)-, -C(O)-, -O-, -N(H)- or -N(C 1-4 Alkyl group). In some embodiments, L is -CH2-, -CHF-, -CF2-, -CH(CH3)-, -C(CH3)2-, -C(CH3)(CF3)-, -C(OH)(H)-, -C(OH)(CH3)-, -C(OH)(CF3)-, -C(O)-, -N(H)-, or -N(C 1-4Alkyl group. In some embodiments, L is -CH2-, -CHF-, -CF2-, -O-, -N(H)-, or -N(C). 1-4 Alkyl group). In some embodiments, L is -CH2-, -CHF-, -CF2-, -N(H)-, or -N(C). 1-4 Alkyl group. In some embodiments, L is -CH2-, -O-, -N(H)-, or -N(C). 1-4 Alkyl group. In some embodiments, L is -CH2-, -O-, -N(H)-, or -N(C). 1-4 Alkyl)-. In some embodiments, L is -N(H)- or -N(C)-. 1-4 Alkyl group). In some embodiments, L is -O-, -N(H)-, or -N(CH3)-. In some embodiments, L is -N(H)- or -N(CH3)-. In some embodiments, L is -O- or -N(H)-. In some embodiments, L is -O-. In some embodiments, L is -N(H)-.

[0075] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 and R 2 It's H, or R. 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group is optionally surrounded by one or more R 2a Replacement. In some implementations, R 1 and R 2 It's H, or R. 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6-membered heterocyclic group, wherein the 4-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution. In some embodiments, R 1 and R 2 It's H, or R. 1 and R 2 Together with the carbon atoms to which they are attached, they form cyclopropyl or N-methylazacyclobutane groups. In some embodiments, R 1 and R 2 Each is H.

[0076] In some embodiments of the compound of formula (I) or a pharmaceutically acceptable salt of any of the foregoing, R 3 and R 4 H and C independently 1-4 Alkyl or C1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a Replacement. In some implementations, R 3 and R 4 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6-membered heterocyclic group, wherein the 3-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution. In some embodiments, R 3 and R 4 Independently, it is H, -CH3, or -CF3, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form cyclopropyl, cyclobutyl, or N-methylazacyclobutane groups.

[0077] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 5 It is H, C 1-2 Alkyl or C 1-2 Halogenated alkyl groups. In some embodiments, R 5 It is H, -CH3, -CH2CH3, -CH2CF3, or -CH2CF2H. In some implementations, R 5 It is H, -CH3, or -CH2CH3. In some implementations, R 5 It is H or -CH3. In some implementations, R 5 It's H.

[0078] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 6 It is H, C 1-2 Alkyl or C 1-2 Halogenated alkyl groups. In some embodiments, R 6 It is H, -CH3, -CH2CH3, -CH2CF3, or -CH2CF2H. In some implementations, R 6 It is H, -CH3, or -CH2CH3. In some implementations, R 6 It is H or -CH3. In some implementations, R 6 It is H. In some implementations, R 5and R 6 Each is H.

[0079] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 1 R 2 R 5 and R 6 Each is H. In some implementations, R 1 R 2 R 3 R 4 R 5 and R 6 Each is H.

[0080] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted 5-6 heteroaryl groups.

[0081] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 The substituted 5-membered heteroaryl group. In some embodiments, R 7 It is a pyrazolyl, oxazolyl, or thiazolyl group, wherein the pyrazolyl, oxazolyl, or thiazolyl group is R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Replacement. In some implementations, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted pyrazol group. In some embodiments, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 The substituted oxazolyl group. In some embodiments, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted thiazole group.

[0082] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 The substituted 6-membered heteroaryl group. In some embodiments, R 7 It is pyrimidinyl, pyridinyl, or pyridazinyl, wherein the pyrimidinyl, pyridinyl, or pyridazinyl is R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Replacement. In some implementations, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted pyrimidine group. In some embodiments, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted pyridinyl group. In some embodiments, R 7 It was R 8 It is substituted at the carbon atom adjacent to the heteroatom and optionally replaced by one or more R atoms. 9 Substituted pyridazine group. In some embodiments, R 7 yes In some implementations, R 7 yes , where R 10 H and C independently 3-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl, wherein the C 3-4 alkyl or the C 1-4 The haloalkyl group is optionally surrounded by one or more R 10a Replacement, and the C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b Replacement. In some implementations, R 7 yes , where R 10 H and C independently 1-4 Halogenated alkyl or C 3-4 cycloalkyl, wherein the C 1-4 The haloalkyl group is optionally surrounded by one or more R 10a Replacement, and the C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b Replacement. In some implementations, R 7 yes , where R 10 It is independently H, methyl or C 3-4 cycloalkyl, wherein the C 3-4cycloalkyl groups are optionally surrounded by one or more R 10b Replacement. In some implementations, R 7 yes , where R 10 Independently, it is H or C 3-4 cycloalkyl, wherein the C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b replace.

[0083] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 It was R 8 Replaced and optionally by one or more R 9 Replaced 8-14 membered heterocyclic groups. In some embodiments, R 7 It is 5,6,7,8-tetrahydropyrido[4,3- d ]pyrimidinyl, wherein the 5,6,7,8-tetrahydropyridyl[4,3- d ]Pyrimidine group is R 8 Replaced and optionally by one or more R 9 Replacement. In some implementations, R 7 It can be arbitrarily divided by 1, 2 or 3 Rs 9 Group substitution In some implementations, R 7 It can be arbitrarily divided by 1 or 2 Rs 9 Group substitution .

[0084] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 8 It is halogenated. In some implementations, R 8 It is Cl or F. In some implementations, R 8 It is Cl. In some implementations, R 8 It is -S(O) n (R 13 In some implementations, R 8 It is -S(O) n (C 1-4 Alkyl group). In some embodiments, R 8 It is -S(O) n (CH3). In some implementations, R 8 It is -S(R) 13 In some implementations, R 8 It is -S(C 1-4 Alkyl group). In some embodiments, R 8It is -S(CH3). In some implementations, R 8 It is -S(O)(R 13 In some implementations, R 8 It is -S(O)(C 1-4 Alkyl group). In some embodiments, R 8 It is -S(O)(CH3). In some implementations, R 8 It is -S(O)2(R) 13 In some implementations, R 8 It is -S(O)2(C 1-4 Alkyl group). In some embodiments, R 8 It is -S(O)2(CH3).

[0085] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 9 It is optionally controlled by one or more R 9a Replacement C 1-4 Alkyl group. In some embodiments, R 9a It is -CN, -OR 10 -C(O)-R 12 -S(O)2(R 12 C 3-6 Cycloalkyl, or optionally substituted with one or more substituents selected from the group consisting of: oxo and -CH3. In some embodiments, R 9a It is -CN, -OR 10 -C(O)-R 12 -S(O)2(R 12 C 3-6 Cycloalkyl, or optionally substituted with one or more substituents selected from the group consisting of: oxo, halogenated, and -CH3. In some embodiments, R 9a It is -CN, -OH, -O(C) 1-4 Alkyl), -O(C) 1-4 Halogenated alkyl), -O(C) 3-6 cycloalkyl), -O (4-6 membered heterocyclic groups), -C(O)-(C 3-6 cycloalkyl), -C(O)-[N(C 1-4 Alkyl)(C 1-4 Alkyl)]、-S(O)2(C 1-4 Alkyl), -S(O)2[N(C 1-4 Alkyl)(C 1-4 [alkyl], C 3-6Cycloalkyl, or 4-10 membered heterocyclic group, wherein the 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and -CH3. In some embodiments, R 9a It is -CN, -OH, -O(C) 1-4 Alkyl), -O(C) 1-4 Halogenated alkyl), -O(C) 3-6 cycloalkyl), -O (4-6 membered heterocyclic groups), -C(O)-(C 3-6 cycloalkyl), -C(O)-[N(C 1-4 Alkyl)(C 1-4 Alkyl)]、-S(O)2(C 1-4 Alkyl), -S(O)2[N(C 1-4 Alkyl)(C 1-4 [alkyl], C 3-6 Cycloalkyl or 4-10 membered heterocyclic groups, wherein the 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and -CH3. In some embodiments, R 9a Selected from the group consisting of: pyrrolidinyl, piperidinyl, piperazinyl, morpholino, isothiazolyl, and 5-azaspiro[2,4]heptyl. In some embodiments, R 9 It is C 1-4 Alkyl group. In some embodiments, R 9 It is -CH3.

[0086] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 9 It is optionally controlled by one or more R 9a C that is replaced and further replaced by one or more deuteriums 1-4 Alkyl group. In some embodiments, R 9 It is -O(C) 1-4 alkyl) substituted C 1-4 Alkyl, wherein the C 1-4 Alkyl or -O(C) 1-4 At least one of the alkyl groups is further substituted with one or more deuterium groups. In some embodiments, R 9 It is -CH3O(CH2CH3).

[0087] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 9 It is optionally controlled by one or more R 9b Replacement C 3-6 Cycloalkyl. In some embodiments, R 9 It is cyclopropyl.

[0088] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 9 It is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl, -CH2S(O)2(C 1-4 Alkyl groups, -CN, -CH2(CN), -CH2(4-8 membered heterocyclic groups), -CH2O(C) 1-4 alkyl), -CH2O(C 1-4 Halogenated alkyl), -CH2O(C 3-6 cycloalkyl), -CH2O (4-6 membered heterocyclic group), -C(O)-(C 1-4 Alkyl), -C(O)-(C 3-6 cycloalkyl), -C(O)-O(C 1-4 Alkyl), -C(O)-N(H)(C 1-4 alkyl) or -C(O)-N(C 1-4 Alkyl)(C 1-4 Alkyl), wherein the -CH2 (4-8 membered heterocyclic group) is optionally substituted by one or more groups selected from: C 1-4 Alkyl and oxo. In some embodiments, R 9 It is halogenated, -CH3, -CF3, -CHF2, -CH2CF3, -CH2CF2H, cyclopropyl, -CH2S(O)2CH3, -CN, -CH2(CN), -CH2(5-7 membered heterocyclic group), -CH2OCH3, -CH2-OCH2CH3, -CH2O(CF3), -CH2O(CHF2), -CH2O(cyclopropyl), -CH2O(tetrahydrofuranyl), -C(O)-CH3, -C(O)-(cyclopropyl), -C(O)-OCH3, -C(O)-N(H)(CH3) or -C(O)-N(CH3)(CH3), wherein the -CH2(5-7 membered heterocyclic group) is optionally substituted by one or more groups selected from the following: -CH3 and oxo.

[0089] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 Choose from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

[0090] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 Choose from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

[0091] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 yes , or , where R 9 yes , , , , , , , , or .

[0092] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 7 Choose from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , and .

[0093] In some embodiments of the compounds of formula (I), any variants or embodiments thereof, or pharmaceutically acceptable salts of any of the foregoing, each R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl; wherein the C 1-4 alkyl or the C 1-4 The haloalkyl group is optionally surrounded by one or more D, -OH, -O(C) groups. 1-4 alkyl) or -O(C 1-4 (Halogenated alkyl) substitution, and the C 3-4 The cycloalkyl group is optionally halogenated or C-substituted. 1-4 Alkyl, C 1-4 Haloalkyl, -O(C)1-4 Alkyl groups, -NH2, -NH(C) 1-4 alkyl) or -N(C) 1-4 Alkyl)(C 1-4 Alkyl) substitution. In some embodiments, R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl; wherein the C 1-4 The alkyl group is optionally substituted with one or more D, -OH, -O(CH3) or -O(CF3), and the C 3-4 The cycloalkyl group may optionally be substituted by one or more F, Cl, Br, -CH3, -O(CH3), -NH2, -NH(CH3) or -N(CH3)(CH3).

[0094] In some embodiments of the compounds of formula (I), any variants or embodiments thereof, or pharmaceutically acceptable salts of any of the foregoing, each R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 Cycloalkyl. In some embodiments, each R 10 Independently, it is H, -CH3, -CH2CH3, CF3, or cyclopropyl. In some embodiments, each R... 10 It can be H, -CH3, or -CH2CH3 independently.

[0095] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, X is CR 11 In some implementations, R 11 It is H or halogenated. In some implementations, R 11 It is H or F. In some implementations, R 11 It is H or Cl. In some implementations, R 11 It is H or Br. In some implementations, X is N.

[0096] In some embodiments of the compounds of formula (I), any variants or embodiments thereof, or pharmaceutically acceptable salts of any of the foregoing, each R 15 and R 16 Is it H, D, or C? 1-4 Alkyl group. In some embodiments, each R 15 and R 16 It is H, D, or -CH3. In some implementations, each R 15 and R 16 It is H or D.

[0097] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 17 It is H, -CH3, or halogenated. In some embodiments of compounds of formula (I) or pharmaceutically acceptable salts of any of the foregoing, R 17 It is H or -CH3. In some embodiments of compounds of formula (I) or pharmaceutically acceptable salts of any of the foregoing, R 17 It is H or halogenated. In some implementations, R 17 It's H.

[0098] In some embodiments of the compound of formula (I), any variant or embodiment thereof, or a pharmaceutically acceptable salt of any of the foregoing, R 18 It is H, -CH3, or halogenated. In some embodiments of compounds of formula (I) or pharmaceutically acceptable salts of any of the foregoing, R 18 It is H or -CH3. In some embodiments of compounds of formula (I) or pharmaceutically acceptable salts of any of the foregoing, R 18 It is H. In some implementations, R 17 and R 18 Both are H.

[0099] In some embodiments of the compounds of formula (I), or any variant or embodiment thereof, or any pharmaceutically acceptable salt of any of the foregoing, the compounds or any pharmaceutically acceptable salts of any of the foregoing are selected from Table 1. In some embodiments of the compounds of formula (I), or any variant or embodiment thereof, or any pharmaceutically acceptable salts of any of the foregoing, the compounds or any pharmaceutically acceptable salts of any of the foregoing are selected from compounds 1-141 in Table 1.

[0100] In one aspect, this document provides compounds, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein said compounds, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, are selected from the compounds listed in Table 1. In some embodiments, the compounds, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, are selected from compounds 1-32 and 34-141 of Table 1. In some embodiments, the compounds, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, are selected from compounds 1-32 and 34-189 of Table 1. In some embodiments, the compounds, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, are selected from compounds 1-32, 34-43, and 45-141 of Table 1. In some embodiments, the compound, or its stereoisomers or tautomers, or a pharmaceutically acceptable salt thereof, is selected from compounds 1-32, 34-43, and 45-189 of Table 1.

[0101] Table 1

[0102] In some embodiments, this document provides a compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein said compound is selected from the group consisting of: 2-((2-chloro-5-((methylsulfonyl)methyl)pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-((methylsulfonyl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((methylsulfonyl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-fluoropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloropyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-Chloro-4-((1'-Fluoro-7'-oxo-5',6',7',8',9',11'-hexahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-2'-yl)oxy)-7,8-dihydropyridino[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloropyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((4-chloropyrimidin-2-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-1-methyl-6',8',9',11'-tetrahydrospiro[azacyclobutane-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((6-chloropyrazin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(morpholinomethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((2-oxopyrrolidone-1-yl)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-((2-oxopyrrolidone-1-yl)methyl)pyrimidin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2,5-dichloropyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2-hydroxy-2-methylpropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(1-methylcyclopropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2,5-dichloropyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-(2-((2,5-dichloropyridin-4-yl)amino)-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one; 2-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-cyclopropylpyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R)-2-((2-chloro-5-((3-methyl-2-oxopyrrolidone-1-yl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; [(R) or (S)]-6-chloro-4-((1-fluoro-10-methyl-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)amino) nicotinic acid methyl ester; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-cyclopropylpyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-oxo-5,6,7,8-tetrahydro-1,6-naphthidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S)-2-((2-chloro-5-(((tetrahydrofuran-3-yl)oxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S)-2-((4-chloro-5-(((tetrahydrofuran-3-yl)oxy)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((5-acetyl-2-chloropyridin-4-yl)amino)-1'-fluoro-1-methyl-6',8',9',11'-tetrahydrospiro[azacyclobutane-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(hydroxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2-((4-chloropyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(hydroxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(2-hydroxypropane-2-yl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(((3S,4R)-3,4-difluoropyrrolidine-1-yl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(((3S,4R)-3,4-difluoropyrrolidine-1-yl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; (S) or (R)-2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(difluoromethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5-oxo-5,6,7,8-tetrahydro-1,6-naphthid-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6,7-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6,7-dimethyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-(ethoxymethyl)pyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(2,2,2-trifluoro-1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 6-Chloro-N,N-Dicyclopropyl-4-((1-Fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)amino)pyridazine-3-carboxamide; 2-((2-chloro-5-(3,4-difluoropyrrolidine-1-carbonyl)pyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((3-acetyl-6-chloropyridazin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; Chloropyridin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((5-acetyl-2-chloropyridin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((6-chloro-3-(ethoxymethyl)pyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2-((2-chloro-5-(3,4-difluoropyrrolidine-1-carbonyl)pyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 6-Chloro-N,N-Dicyclopropyl-4-((1-Fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)oxy)pyridazine-3-carboxamide; 2-((2-chloro-5-(trifluoromethyl)pyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[oxetane-2,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-11-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-(4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-1-fluoro-11-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':3,4]cyclopentan[1,2-f]isoquinoline-7-one; 2-((6-chloropyrimidin-4-yl)methyl)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-5',6',8',9'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2'-((4-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-1'-fluoro-5',6',8',9'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2-(2-chloro-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; (S) or (R)-2-((2-chloro-5-(1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; (R) or (S)-2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-4-[2-chloro-5-(difluoromethoxymethyl)-4-pyrimidinyloxy]-3-fluoro-14-methyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2(7),3,5,11(16)-pentaen-12-one;] 2'-((4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)oxy)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; (R) or (S)-2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((5-((difluoromethoxy)methyl)-4-iodopyrimidin-2-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trans-3,4-difluoropyrrolidine-1-yl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((prop-2-yn-1-yloxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-4-[2-chloro-5-(cyclopropoxymethyl)-4-pyrimidinyloxy]-3-fluoro-15-methyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2(7),3,5,11(16)-pentaen-12-one;] (R) or (S)-2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-4-[2-chloro-5-(cyclopropoxymethyl)-4-pyrimidinyloxy]-3-fluoro-15-methyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2(7),3,5,11(16)-pentaen-12-one;] (S) or (R)-2-((2-chloro-6-cyclobutyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-8,9,10,11-tetrahydro-5H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; (R) or (S)-2-((2-chloro-6-cyclobutyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-8,9,10,11-tetrahydro-5H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; (R) or (S)-2-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-8,9,10,11-tetrahydro-5H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; (S) or (R)-2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-8,9,10,11-tetrahydro-5H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 4-(2-Chloro-6-ethyl-5,6,7,8-tetrahydro-1,3,6-triaza-4-naphthyloxy)-3-fluoro-15,15-dimethyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one;] (R) or (S)-4-(2-chloro-6-ethyl-5,6,7,8-tetrahydro-1,3,6-triaza-4-naphthyloxy)-3-fluoro-14-methyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one;] (S) or (R)-4-(2-chloro-6-ethyl-5,6,7,8-tetrahydro-1,3,6-triaza-4-naphthyloxy)-3-fluoro-14-methyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one;] 4-(2-Chloro-6-ethyl-5,6,7,8-tetrahydro-1,3,6-triaza-4-naphthyloxy)-3-fluoro-14,14-dimethyl-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one;] (S) or (R)-2-((2-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((5-acetyl-2-chloropyridin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((5-acetyl-2-chloropyridin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; (S) or (R)-2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((4-chloro-5-((difluoromethoxy)methyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((4-chloro-5-((difluoromethoxy)methyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; and (R) or (S)-2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one.

[0103] In some embodiments, this document provides a compound or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein said compound is selected from the group consisting of: 2-((2-chloro-5-((methylsulfonyl)methyl)pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-((methylsulfonyl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((methylsulfonyl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-fluoropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloropyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-Chloro-4-((1'-Fluoro-7'-oxo-5',6',7',8',9',11'-hexahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-2'-yl)oxy)-7,8-dihydropyridino[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((4-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloropyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((4-chloropyrimidin-2-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-1-methyl-6',8',9',11'-tetrahydrospiro[azacyclobutane-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((6-chloropyrazin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(morpholinomethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((2-oxopyrrolidone-1-yl)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-((2-oxopyrrolidone-1-yl)methyl)pyrimidin-2-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2,5-dichloropyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2-hydroxy-2-methylpropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(1-methylcyclopropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2,5-dichloropyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-(2-((2,5-dichloropyridin-4-yl)amino)-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one; 2-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-cyclopropylpyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R)-2-((2-chloro-5-((3-methyl-2-oxopyrrolidone-1-yl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; [(R) or (S)]-6-chloro-4-((1-fluoro-10-methyl-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)amino) nicotinic acid methyl ester; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-cyclopropylpyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-oxo-5,6,7,8-tetrahydro-1,6-naphthidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S)-2-((2-chloro-5-(((tetrahydrofuran-3-yl)oxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S)-2-((4-chloro-5-(((tetrahydrofuran-3-yl)oxy)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloropyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-(trifluoromethyl)pyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((5-acetyl-2-chloropyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((5-acetyl-2-chloropyridin-4-yl)amino)-1'-fluoro-1-methyl-6',8',9',11'-tetrahydrospiro[azacyclobutane-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(hydroxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2-((4-chloropyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(hydroxymethyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(2-hydroxypropane-2-yl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(((3S,4R)-3,4-difluoropyrrolidine-1-yl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((4-chloro-5-(((3S,4R)-3,4-difluoropyrrolidine-1-yl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; (S) or (R)-2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((4-chloro-5-(ethoxymethyl)pyrimidin-2-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (S) or (R)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; (R) or (S)-2-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(difluoromethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6-cyclopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5-oxo-5,6,7,8-tetrahydro-1,6-naphthid-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6,7-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-cyclopropyl-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-ethyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-6,7-dimethyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((6-chloro-3-(ethoxymethyl)pyridazin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(2,2,2-trifluoro-1-hydroxyethyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-(cyclopropoxymethyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)oxy)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 6-Chloro-N,N-Dicyclopropyl-4-((1-Fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)amino)pyridazine-3-carboxamide; 2-((2-chloro-5-(3,4-difluoropyrrolidine-1-carbonyl)pyridin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((3-acetyl-6-chloropyridazin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; Chloropyridin-4-yl)amino)-1-fluoro-9-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((5-acetyl-2-chloropyridin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((6-chloro-3-(ethoxymethyl)pyridazin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((trifluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloro-5-((difluoromethoxy)methyl)pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; 2'-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-8',9'-dihydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one; 2-((2-chloro-5-(3,4-difluoropyrrolidine-1-carbonyl)pyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2-((2-chloropyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 6-Chloro-N,N-Dicyclopropyl-4-((1-Fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)oxy)pyridazine-3-carboxamide; 2-((2-chloro-5-(trifluoromethyl)pyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one; 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[oxetane-2,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one; and 2-((2-chloro-5-(oxecyclobutan-2-yl)pyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one.

[0104] Pharmaceutical Composition This document provides pharmaceutical compositions comprising one or more compounds of formula (I), or any variant or embodiment thereof (as described elsewhere herein), or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, this document provides pharmaceutical compositions comprising (i) a compound of formula (I), or any variant or embodiment thereof (as described elsewhere herein), or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In some embodiments, the composition comprises a therapeutically effective amount of the compound.

[0105] Suitable pharmaceutically acceptable excipients may include, for example, fillers, diluents, sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers and adjuvants. The term excipient may cover a wide range of substances, including but not limited to any substance used as a binder, disintegrant, coating, tableting / encapsulation aid, cream or lotion, lubricant, solution for parenteral administration, material for chewable tablets, sweetener or flavoring agent, suspending / gelling agent or wet granulation agent. Examples of suitable excipients are well known to those skilled in the art. See, for example, Handbook of Pharmaceutical Excipients ,Pharmaceutical Press (2017), which is incorporated herein by reference in its entirety. Such compositions are prepared in a manner well known in the pharmaceutical field. See, for example, Remington's Pharmaceutical Sciences , Academic Press, 23rd edition (2020), which is incorporated herein by reference in its entirety.

[0106] Treatment The MAP kinase pathway is associated with a wide range of diseases, including but not limited to autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurodegenerative diseases, cancer, cardiovascular diseases, respiratory diseases, Alzheimer's disease, and hormone-related diseases. MAP kinase inhibitors are being sought as therapeutic agents. See, for example, U.S. Patent Nos. 10,138,256 B2 and 11,098,061, each of which is incorporated herein by reference in its entirety.

[0107] Compounds exhibiting inhibitory activity against mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) have also been reported in the literature for use in the treatment of certain inflammatory disorders. See, for example, U.S. Patent Application Publication No. 2016 / 0075720, U.S. Patent Application Publication No. 2022 / 0251105, U.S. Patent Application Publication No. 2023 / 0255979, and International Patent Applications WO 2020 / 236636 and WO 2022 / 020562, each of which is incorporated herein by reference in its entirety. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) has been reported in the literature to mediate various p38 MAPK-dependent cellular responses. See, for example, U.S. Patent Application Publication No. 2016 / 0075720, which is hereby incorporated herein by reference in its entirety. MK2 has also been reported as an important intracellular regulator of cytokine production, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interferon-γ (IFNg), each involved in several acute and chronic inflammatory diseases. MK2 is also involved in the regulation of heart failure, ischemic brain injury, stress resistance, and TNF-α production. See, for example, Deak et al., EMBO. 17:4426-4441 (1998); Shi et al., Biol. Chem .383:1519-1536 (2002); Staklatvala., Curr. Opin. Pharmacol 4:372-377 (2004); Shiroto et al., J. Mol. Cardiol 38:93-97 (2005); Vittal et al., Am. J. Respir. Cell Mol. Biol. 49: 47-57 (2013); Murgo et al. Front. Pharmacol. 14: 1303646 (2023); and Ward, et al. J. Pept. Sci. 15: 668-674 (2009), each of which is incorporated herein by reference in its entirety.

[0108] In one aspect, a method is provided for treating a disease or condition mediated by MK2, the method comprising administering to a subject in need a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or any of the foregoing). Pharmaceutically acceptable salts, or compounds comprising formula (I) or any variants or embodiments thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, compounds selected from compounds 1-32, 34-43 and 45-189 of Table 1, or their stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, and pharmaceutical compositions comprising one or more pharmaceutically acceptable excipients.In some embodiments, a therapeutically effective amount of a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or containing formula (Ia-1), is administered. Compounds of (I) or any variants or embodiments thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, compounds selected from compounds 1-32, 34-43 and 45-189 of Table 1, or their stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, and pharmaceutical compositions of one or more pharmaceutically acceptable excipients.

[0109] In some implementations, the subjects are humans.

[0110] In some implementations, the diseases or conditions mediated by MK2 are inflammatory joint diseases, systemic diseases or connective tissue diseases, neurodegenerative or neuroinflammatory diseases, inflammatory bowel diseases, cutaneous autoimmune disorders, ocular autoimmune diseases, respiratory diseases, or diabetes.

[0111] In some embodiments, the disease or condition mediated by MK2 is a fibrotic disease. In some embodiments, the disease or condition is pulmonary fibrosis, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), or liver fibrosis. In some embodiments, the disease or condition is pulmonary fibrosis or liver fibrosis. In some embodiments, the disease or condition is idiopathic pulmonary fibrosis. In some embodiments, the disease or condition is non-alcoholic steatohepatitis (NASH).

[0112] In some implementations, inflammatory arthropathy includes rheumatoid arthritis, juvenile arthritis, Still's disease, juvenile rheumatoid arthritis, systemic flare-up rheumatoid arthritis, oligoarticular rheumatoid arthritis, oligoarticular juvenile rheumatoid arthritis, polyarticular rheumatoid arthritis, enteropathic arthritis, juvenile Reiter's syndrome, ankylosing spondylitis, juvenile ankylosing spondylitis, SEA syndrome, reactive arthritis (reactive arthropathy), psoriatic arthropathy, psoriatic arthritis, juvenile enteropathic arthritis, polymyalgia rheumatica, enteropathic spondylitis, juvenile idiopathic arthritis (JIA), juvenile psoriatic arthritis, systemic flare-up juvenile rheumatoid arthritis, giant cell arteritis, or secondary osteoarthritis caused by inflammatory diseases.

[0113] In some implementations, the systemic disease or connective tissue disorder is lupus, systemic lupus erythematosus, juvenile systemic lupus erythematosus, nephritis, Sjögren's syndrome, scleroderma (systemic sclerosis), Raynaud's phenomenon, juvenile scleroderma, polymyositis, dermatomyositis, polymyositis-dermatomyositis, polymyalgia rheumatica, mixed connective tissue disease, sarcoidosis, fibromyalgia, microscopic polyangiitis obliterans, vasculitis, eosinophilic granulomatous polyangiitis (formerly known as Chalger-Strauss syndrome), granulomatous polyangiitis (formerly known as Wegener's granulomatosis), polyarteritis nodosa, allergic purpura, idiopathic thrombocytopenic purpura, juvenile vasculitis, and nodular hyperactivity. Panarteritis (also known as nodular panarteritis, nodular periarteritis, Cusmore disease, Cusmore-McMoRan disease, or PAN), serum sickness, myasthenia gravis, Takayasu arteritis, Behçet's syndrome, Kawasaki disease (mucocutaneous lymph node syndrome), Berger's disease (thromboangiitis obliterans), Vogt-Koyanagi-Harada syndrome, Addison's disease, Hashimoto's thyroiditis, primary biliary sclerosis, autoimmune hepatitis, chronic active hepatitis, non-alcoholic fatty liver disease, sclerosing cholangitis, membranous glomerulonephritis, polymyositis, myositis, atherosclerosis, autoimmune hemolytic anemia, autoimmune orchitis, Goodpasture's disease, chronic graft-versus-host disease, acute graft-versus-host disease, or Sjögren's syndrome.

[0114] In some implementations, neurodegenerative and neuroinflammatory diseases are multiple sclerosis, amyotrophic lateral sclerosis, Guillain-Barré syndrome, autoimmune encephalomyelitis, Alzheimer's disease, major depressive disorder, traumatic brain injury, epilepsy, Parkinson's disease, or bipolar disorder.

[0115] In some implementations, inflammatory bowel disease is Crohn's disease, ulcerative colitis, celiac disease, proctitis, eosinophilic gastroenteritis, autoimmune atrophic gastritis with pernicious anemia, or mastocytosis.

[0116] In some implementations, the skin autoimmune disorder is psoriasis, atopic dermatitis, eczematous dermatitis, dermatitis, pruritus, epidermal hyperplasia, juvenile dermatomyositis, dermatomyositis, or hidradenitis suppurativa. In some implementations, psoriasis is plaque psoriasis, guttate psoriasis, psoriatic epidermal hyperplasia, inverted psoriasis, pustular psoriasis, or erythrodermic psoriasis.

[0117] In some implementations, ocular autoimmune diseases are ocular manifestations of Graves' disease, non-infectious uveitis, dry eye syndrome, sympathetic ophthalmia, Cole's syndrome, keratoconjunctivitis, vernal conjunctivitis, uveitis (including uveitis associated with Behçet's disease and lens-induced uveitis), keratitis, herpetic keratitis, keratoconus, corneal epithelial dystrophy, corneal leukoma, ocular pemphigoid, keratodermal ulcer, scleritis, keratoconjunctivitis sicca (dry eye syndrome), small bullae, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmia, allergic conjunctivitis, ocular neovascularization, or other autoimmune diseases.

[0118] In some implementations, respiratory diseases are asthma, chronic obstructive pulmonary disease, or acute respiratory diseases.

[0119] In some implementations, the disease or condition mediated by MK2 is type 1 diabetes, type 2 diabetes, or juvenile-onset diabetes.

[0120] In some implementations, diseases or conditions mediated by MK2 are selected from the group consisting of: rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, cryopyridine-associated periodic syndrome (CAPS), juvenile idiopathic arthritis (JIA), and pancreatic cancer.

[0121] In some implementations, the disease or condition mediated by MK2 is a cancer selected from the group consisting of: pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal carcinoma, skin cancer, bladder cancer, prostate cancer, head and neck cancer, and glioblastoma. In some implementations, the disease or condition mediated by MK2 is pancreatic cancer.

[0122] In one aspect, this document provides a method for inhibiting MK2 activity, the method comprising contacting MK2 with: an effective amount of a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a drug of any of the foregoing. Pharmaceutical compositions comprising a pharmaceutically acceptable salt, or a compound comprising formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0123] In one aspect, this document provides a method for covalently modifying MK2, the method comprising contacting MK2 with: an effective amount of a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutical product of any of the foregoing. Pharmaceutical compositions comprising a pharmaceutically acceptable salt, or a compound comprising formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0124] In one aspect, this document provides covalently modified MK2, which is formed by contacting MK2 with: an effective amount of a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or pharmaceutically acceptable forms of any of the foregoing. Pharmaceutical compositions comprising a pharmaceutically acceptable salt, or a compound comprising formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0125] In one aspect, this document provides compounds of formula (I), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, or compounds comprising formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, compounds selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing). A pharmaceutical composition, or a compound comprising formula (I) or any variation or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients, for use in the treatment of a disease or condition mediated by MK2.

[0126] In one aspect, this document provides compounds of formula (I) or any variations or embodiments thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, compounds selected from compounds 1-32, 34-43 and 45-189 of Table 1, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, or compounds comprising formula (I) or any variations or embodiments thereof. The use of a pharmaceutical composition comprising (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease or condition mediated by MK2.

[0127] Reagent test kit This disclosure further provides kits for implementing the methods disclosed herein. The kit may contain a compound as described herein or a pharmaceutically acceptable salt thereof, along with suitable packaging. The kit may contain one or more containers containing any of the compounds described herein. In one aspect, the kit includes a compound of this disclosure or a pharmaceutically acceptable salt thereof, along with a label and / or instructions for using the compound to treat the disease or condition described herein. The kit may contain unit dosage forms of the compound.

[0128] This document provides a kit comprising (i) an effective amount of a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating MK2-mediated diseases, disorders or conditions in individuals in need. This document also provides a kit comprising (i) a pharmaceutical composition comprising an effective amount of a compound of formula (I) or any variation or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating MK2-mediated diseases, disorders or conditions in an individual in need. In some embodiments, the individual is a person.

[0129] This document provides a kit comprising (i) a compound of formula (I) or any variant or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating MK2-mediated diseases, disorders or conditions in individuals in need. This document also provides a kit comprising (i) a pharmaceutical composition comprising a compound of formula (I) or any variation or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating MK2-mediated diseases, disorders or conditions in an individual in need. In some embodiments, the individual is a person.

[0130] Articles are also provided, wherein the articles comprise, in a suitable container, a compound of formula (I) or any variation or embodiment thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), a compound selected from the compounds listed in Table 1, a compound selected from compounds 1-32, 34-43 and 45-189 of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. This document also provides articles comprising pharmaceutical compositions in suitable containers, said pharmaceutical compositions comprising compounds of formula (I) or any variations or embodiments thereof (e.g., (Ia-1), (Ia-2), (Ib-1), (Ib-2), (Ic-1), (Ic-2), (Id-1), (Id-2), (Ie-1), (Ie-2), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Im), (In), (Io)), compounds selected from those listed in Table 1, compounds selected from compounds 1-32, 34-43 and 45-189 of Table 1, or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. The container may be a vial, wide-mouth bottle, ampoule, pre-filled syringe, or intravenous infusion bag.

[0131] Preparation method This document provides methods for preparing compounds of formula (I), any variations or embodiments thereof, or pharmaceutically acceptable salts of any of the foregoing. The synthetic methods detailed below, along with those detailed in the embodiments and examples, illustrate only some methods by which the disclosed compounds or embodiments or aspects thereof may be synthesized. Various modifications can be made to these synthetic reaction schemes, as will be apparent to those skilled in the art. Although certain exemplary embodiments are described and illustrated herein, the compounds of this disclosure, or any variations or embodiments thereof, may be prepared using suitable starting materials according to the methods generally described herein and / or by methods available to those skilled in the art.

[0132] When the following general procedure shows a specified stereoisomer, or an unspecified stereoisomer, or a mixture of stereoisomers, it should be understood that a similar chemical transformation may be performed on other specified stereoisomers, or unspecified stereoisomers, or mixtures thereof.

[0133] When a particular reagent or solvent is specified for a reaction in a general procedure, those skilled in the art will recognize that other reagents or solvents may be substituted as needed.

[0134] General Procedure 1 Ag₂CO₃ or Cs₂CO₃ (3.0 equivalent) was added to a solution of the core (1.0 equivalent) and warhead (1.5 equivalent) in DMSO (20 volumes) at 25 °C. The reaction mixture was stirred at 80 °C for several hours and monitored by LCMS. Once the core was completely consumed and a main peak with the desired m / z was detected, the reaction solution was cooled to 20 °C and then poured into MeOH (100 volumes). The quenched reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to remove most of the solvent. The solution was slowly added to ice water (50 volumes), and the precipitated solid was collected by filtration. The solid agglomerates were purified by column chromatography (SiO₂, DCM / MeOH = 1:0 to 10:1) and preparative TLC (EtOAc / MeOH = 10:1). The product was obtained as a brownish-grayish-white solid.

[0135] General Procedure 2 The core (1.0 equivalent) and Cs₂CO₃ (3.0 equivalent) were added to a solution of the core (1.0 equivalent) in DMSO (20 volumes) at 20 °C. The resulting mixture was then stirred at 50 °C until LCMS showed complete consumption of the starting material and a new peak with the desired m / z was detected. The reaction mixture was treated with water (20 volumes) and extracted with ethyl acetate (3 x 10 volumes). The combined organic phases were washed with brine (10 volumes), dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was purified by preparative TLC (petroleum ether:ethyl acetate:NH₃H₂O = 10:1:0.1) to give the product as a brown to grayish-white solid.

[0136] General Procedure 3: A solution of the core (1.0 equivalent) in 1,4-dioxane (10 volumes) was added at 25 °C to a solution containing the core (1.0 equivalent), Xantphos (0.2 equivalent), Pd2(dba)3 (0.1 equivalent), and Cs2CO3 (3 equivalent). The reaction mixture was stirred at 100 °C until LCMS showed complete consumption of the core and a peak with the desired m / z was detected. The suspension was filtered through a silica gel pad, and the filter cake was washed with ethyl acetate (3 x 20 volumes). The combined organic matter was washed with H2O (10 volumes) and saturated aqueous NaCl solution (10 volumes), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 0 / 1) to give the final product (sometimes based on regioisomers of substituted chlorine groups) as a brown to grayish-white solid.

[0137] List of implementation plans Example 1. A compound of formula (I): (I), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein: L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R) 10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further surrounded by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R 13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R)10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and R. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-4 cycloalkyl; Wherein C 1-4 alkyl or the C 1-4 The haloalkyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl groups are optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR 14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14 (R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 or -N(R) 14 (R) 14 ); R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl groups; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18 It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups.

[0138] Scheme 2 is listed. The compound according to Scheme 1 is wherein: R 5 Is it H or C? 1-2 alkyl; R 6 Is it H or C? 1-2 alkyl; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 quinone heteroaryl, among which The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and R. 14 And each R 4a It is C 1-4 alkyl.

[0139] Example 3. The compound according to example 1 or 2, wherein the compound is a compound of formula (Ia-1): (Ia-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

[0140] Listed Embodiment 4. The compound according to listed Embodiment 1 or 2, wherein the compound is a compound of formula (Ia-2): (Ia-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

[0141] 5. The compound according to embodiment 1 or 2, wherein the compound is a compound of formula (Ib-1): (Ib-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0142] Listed Embodiment 6. The compound according to listed Embodiment 1 or 2, wherein the compound is a compound of formula (Ib-2): (Ib-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0143] 7. The compound according to embodiment 1 or 2, wherein the compound is a compound of formula (Ic-1): (Ic-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0144] 8. The compound according to embodiment 1 or 2, wherein the compound is a compound of formula (Ic-2): (Ic-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0145] Example 9. The compound according to example 1 or 2, wherein the compound is a compound of formula (Id-1): (Id-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0146] Example 10. The compound according to example 1 or 2, wherein the compound is a compound of formula (1d-2): (Id-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

[0147] 11. A compound according to any one of the listed embodiments 1-4, or a pharmaceutically acceptable salt thereof, wherein L is -C(R 17 (R) 18 -, -O-, or -NR 10 -

[0148] 12. A compound according to any one of the listed embodiments 1-4 or 11, or a pharmaceutically acceptable salt thereof, wherein L is -CH2-, -CHF-, -CF2-, -O-, -N(H)- or -N(C 1-4 alkyl)-.

[0149] 13. A compound according to any one of the listed embodiments 1-4, 11 or 12, or a pharmaceutically acceptable salt thereof, wherein in some embodiments, L is -O-, -N(H)- or -N(C)-. 1-4 alkyl)-.

[0150] 14. The compound according to any one of the listed embodiments 1-13, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group is optionally surrounded by one or more R 2a replace.

[0151] 15. A compound according to any one of the listed embodiments 1-14, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6-membered heterocyclic group, wherein the 4-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution.

[0152] 16. The compound according to any one of the listed embodiments 1-15, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form cyclopropyl or N-methylazacyclobutane groups.

[0153] 17. A compound according to any one of the listed embodiments 1-16, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Each is H.

[0154] 18. The compound according to any one of the listed embodiments 1-17, or a pharmaceutically acceptable salt thereof, wherein: R 3 and R 4 H and C independently 1-4 Alkyl or C1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace.

[0155] 19. The compound according to any one of the listed embodiments 1-18, or a pharmaceutically acceptable salt thereof, wherein: R 3 and R 4 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6-membered heterocyclic group, wherein the 3-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution.

[0156] 20. The compound according to any one of the listed embodiments 1-19, or a pharmaceutically acceptable salt thereof, wherein: R 3 and R 4 Independently, it is H, -CH3, or -CF3, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form cyclopropyl, cyclobutyl, or N-methylazacyclobutane groups.

[0157] 21. The compound according to any one of the listed embodiments 1 or 3-20, or a pharmaceutically acceptable salt thereof, wherein R 5 It is H, C 1-2 Alkyl or C 1-2 Halogenated alkyl groups.

[0158] 22. The compound according to any one of the listed embodiments 1 or 3-21, or a pharmaceutically acceptable salt thereof, wherein R 5 It is H, -CH3, -CH2CH3, -CH2CF3 or -CH2CF2H.

[0159] 23. The compound according to any one of the listed embodiments 1 or 3-22, or a pharmaceutically acceptable salt thereof, wherein R 6 It is H, C 1-2 Alkyl or C 1-2Halogenated alkyl groups.

[0160] 24. The compound according to any one of the listed embodiments 1 or 3-23, or a pharmaceutically acceptable salt thereof, wherein R 6 It is H, -CH3, -CH2CH3, -CH2CF3 or -CH2CF2H.

[0161] 25. The compound according to any one of the listed embodiments 1-24, or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 Each is H.

[0162] 26. The compound according to any one of the listed embodiments 1-25, or a pharmaceutically acceptable salt thereof, wherein R 1 R 2 R 5 and R 6 Each is H.

[0163] 27. The compound according to any one of the listed embodiments 1-26, or a pharmaceutically acceptable salt thereof, wherein R 1 R 2 R 3 R 4 R 5 and R 6 Each is H.

[0164] 28. A compound according to any one of the listed embodiments 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 5-6 heteroaryl groups.

[0165] 29. The compound according to any one of the listed embodiments 1-28, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 5-membered heteroaryl group.

[0166] 30. The compound according to any one of the listed embodiments 1-29, wherein R 7 It is a pyrazolyl, oxazolyl, or thiazolyl group, wherein the pyrazolyl, oxazolyl, or thiazolyl group is R 8 Replaced and optionally by one or more R 9 replace.

[0167] 31. The compound according to any one of the listed embodiments 1-28, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 6-membered heteroaryl group.

[0168] 32. The compound according to any one of the listed embodiments 1-28 or 31, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted pyrimidine group.

[0169] 33. A compound according to any one of the listed embodiments 1-28 or 31, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a pyridinyl group, wherein the pyridinyl group is R 8 Replaced and optionally by one or more R 9 replace.

[0170] 34. The compound according to any one of the listed embodiments 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 8-14 membered heterocyclic groups.

[0171] 35. A compound according to any one of the listed embodiments 1-27 or 34, or a pharmaceutically acceptable salt thereof, wherein R 7 It is 5,6,7,8-tetrahydropyrido[4,3- d ]pyrimidinyl, wherein the 5,6,7,8-tetrahydropyridyl[4,3- d Pyrimidine is R 8 Replaced and optionally by one or more R 9 replace.

[0172] 36. The compound according to any one of the listed embodiments 1-35, or a pharmaceutically acceptable salt thereof, wherein R 8 It is halogenated.

[0173] 37. The compound according to any one of the listed embodiments 1-36, or a pharmaceutically acceptable salt thereof, wherein R 8 It is either Cl or F.

[0174] 38. A compound according to any one of the listed embodiments 1-37, or a pharmaceutically acceptable salt thereof, wherein R 8 It is Cl.

[0175] 39. The compound according to any one of the listed embodiments 1-38, or a pharmaceutically acceptable salt thereof, wherein R 9 It is optionally controlled by one or more R 9a Replacement C 1-4 alkyl.

[0176] 40. The compound according to any one of the listed embodiments 1-39, wherein R 9a It is -CN, -OR 10 -C(O)-R 12 -S(O)2-(R 12 C 3-6 Cycloalkyl or 4-10-membered heterocyclic group, wherein the 4-10-membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and -CH3.

[0177] 41. The compound according to any one of the listed embodiments 1-40, wherein R 9a It is -CN, -OH, -O(C) 1-4 Alkyl), -O(C) 1-4 Halogenated alkyl), -O(C) 3-6 cycloalkyl), -O (4-6 membered heterocyclic groups), -C(O)-(C 3-6 cycloalkyl), -C(O)-[N(C 1-4 Alkyl)(C 1-4 Alkyl)]、-S(O)2-(C 1-4 Alkyl), -S(O)2-N(C 1-4 Alkyl)(C 1-4 Alkyl), C 3-6 Cycloalkyl or 4-10-membered heterocyclic group, wherein the 4-10-membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo and -CH3.

[0178] 42. The compound according to any one of the listed embodiments 1-41, wherein R 9a The following groups are selected: pyrrolidinyl, piperidinyl, piperazinyl, morpholino, isothiazolyl and 5-azaspiro[2.4]heptyl.

[0179] 43. The compound according to any one of the listed embodiments 1-39, wherein R 9 It is C1-4 alkyl.

[0180] 44. The compound according to any one of the listed embodiments 1-39 or 43, wherein R 9 It is -CH3.

[0181] 45. The compound according to any one of the listed embodiments 1-38, or a pharmaceutically acceptable salt thereof, wherein R 9 It is optionally controlled by one or more R 9b Replacement C 3-6 Cycloalkyl.

[0182] 46. ​​A compound according to any one of the listed embodiments 1-38 or 45, or a pharmaceutically acceptable salt thereof, wherein R 9 It is cyclopropyl.

[0183] 47. The compound according to any one of the listed embodiments 1-29, 32 or 33, wherein R 7 yes .

[0184] 48. The compound according to any one of the listed embodiments 1-27 or 34-38, wherein R 7 It can be arbitrarily divided by 1, 2 or 3 Rs 9 Group substitution .

[0185] 49. The compound according to any one of the listed embodiments 1-27 or 34-38, wherein R 7 It can be arbitrarily divided by 1 or 2 Rs 9 Group substitution .

[0186] 50. The compound according to any one of the listed embodiments 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 Choose from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

[0187] 51. A compound according to any one of the listed embodiments 1, 2, 4, 6, 8 or 10-50, or a pharmaceutically acceptable salt thereof, wherein X is a CR 11 .

[0188] Listed Embodiment 52. The compound according to listed Embodiment 51, or a pharmaceutically acceptable salt thereof, wherein R 11 It is H or halogenated.

[0189] Listed Embodiment 53. The compound according to listed Embodiment 51 or 52, or a pharmaceutically acceptable salt thereof, wherein R 11 It is H or F.

[0190] 54. A compound, or a pharmaceutically acceptable salt thereof, according to any one of the listed embodiments 1-3, 5, 7, 9, 11 or 11-50, wherein X is N.

[0191] Example 55. A compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, is selected from Table 1.

[0192] Example 56. A pharmaceutical composition comprising a compound according to any one of the listed embodiments 1-55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0193] Example 57. A method for treating a disease or condition mediated by MK2, comprising administering to a subject in need a compound according to any one of Examples 1-55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to Example 56.

[0194] Example 58. The method according to example 57, wherein a therapeutically effective amount of the compound is administered.

[0195] Example 59. The method according to example 57 or 58, wherein the disease or condition mediated by MK2 is an inflammatory disorder.

[0196] 60. The method described in 57 or 58, wherein the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, celiac disease, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjögren's syndrome, scleroderma, ulcerative colitis, asthma, uveitis, psoriatic arthritis, hidradenitis suppurativa, cryopyridine-associated periodic syndrome, or juvenile idiopathic arthritis.

[0197] Listed Implementation Scheme 61. The method described according to listed implementation schemes 57 or 58, wherein the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, celiac disease, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjögren's syndrome, scleroderma, ulcerative colitis, or asthma.

[0198] Listed Implementation Scheme 62. The method according to listed implementation schemes 57 or 58, wherein the disease or condition mediated by MK2 is rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, cryopyridine-associated periodic syndrome, or juvenile idiopathic arthritis.

[0199] Listed implementation scheme 63. The method according to listed implementation scheme 57 or 58, wherein the disease or condition mediated by MK2 is selected from the following cancers: pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal carcinoma, skin cancer, bladder cancer, prostate cancer, head and neck cancer, or glioblastoma.

[0200] Listed implementation scheme 64. The method according to listed implementation scheme 57 or 58, wherein the disease or condition mediated by MK2 is pancreatic cancer.

[0201] 65. The method according to any one of the listed embodiments 57-64, wherein the subject is a human being.

[0202] Example 66. A method for inhibiting MK2 activity, comprising contacting MK2 with an effective amount of the compound according to any one of Examples 1-55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof.

[0203] Example 67. A method for covalently modifying MK2, comprising contacting MK2 with an effective amount of the compound according to any one of Examples 1-55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof.

[0204] Example 68. A covalently modified MK2, which is formed by the method according to example 67.

[0205] Example 69. A compound, stereoisomer or tautomer thereof, pharmaceutically acceptable salt thereof, or pharmaceutical composition according to any one of Examples 1-55, for use in the treatment of MK2-mediated diseases or disorders.

[0206] Example 70. Use of a compound, stereoisomer or tautomer thereof, pharmaceutically acceptable salt thereof, or pharmaceutical composition according to any one of Examples 1-55 in the manufacture of a medicament for treating diseases or disorders mediated by MK2.

[0207] Example 71. A kit comprising: (i) a compound according to any one of Examples 1-55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Example 56, and (ii) instructions for use in treating MK2-mediated diseases or conditions in individuals in need.

[0208] Example The following synthetic reaction schemes detailed in the schemes and examples illustrate only some methods for synthesizing the disclosed compounds or embodiments or aspects thereof. Various modifications can be made to these synthetic reaction schemes, which will be apparent to those skilled in the art.

[0209] If necessary, conventional techniques, including but not limited to filtration, distillation, crystallization, and chromatography, can be used to separate and purify the starting materials and intermediates of the synthetic reaction. Conventional methods (including physical constants and spectroscopic data) can be used to characterize these materials.

[0210] Although certain exemplary embodiments are described and illustrated herein, the compounds disclosed herein, or any variations or embodiments thereof, may be prepared using suitable starting materials in accordance with the methods generally described herein and / or by means available to those skilled in the art.

[0211] Synthesis Examples As depicted in the schemes and examples below, in certain exemplary embodiments, compounds of formula (I), or any variations or embodiments thereof (as described elsewhere herein), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, are prepared according to a general procedure. The general methods described below, as well as other methods known to a synthetic chemist of ordinary skill in the art, are applicable to all formulas, embodiments, and types described herein.

[0212] Example 1 – Synthesis of 2-((2-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (Compound 1) Step 1. 4-Hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 Preparation of heptadec-1(10),2,4,6,11(16)-pentaen-12-one. 4-Chloro-12-oxo-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 A solution of tert-butyl heptadecanoate-1(10),2,4,6,11(16)-pentane-13-carboxylate (0.1 g, 1 equivalent, 267 µmol) in water (1 mL) and acetic acid (3 mL) was heated to 145 °C and stirred at 145 °C for 6 hours under microwave conditions. LCMS showed that the starting feed peak was consumed and the desired peak was detected. Four additional vials were prepared as described above. After cooling to 25 °C, the five reaction mixtures were combined and concentrated under reduced pressure to give the residue. The residue was purified by preparative TLC (ethyl acetate / methanol = 1 / 1, Rf = 0.3) to give 0.2 g (58.58%) of 4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0]. 2 , 7 .0 11 , 16 [Heptadecyl-1(10),2,4,6,11(16)-pentaen-12-one, a brown solid. LCMS (ESI+): Rt = 0.427 min, m / z 256.2 (M+H) + .

[0213] Step 2.2 Preparation of 4-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)oxy)-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one. 2 , 7 .0 11 , 16Heptadecano-1(10),2,4,6,11(16)-pentaen-12-one (50 mg, 1 equivalent, 196 µmol) was added to a solution of dimethyl sulfoxide (1 mL) at 25 °C along with 2,4-dichloro-5-(methanesulfonyl-methyl)pyrimidine (47.2 mg, 1 equivalent, 196 µmol) and cesium carbonate (128 mg, 2 equivalent, 392 µmol). The resulting mixture was stirred at 25 °C for 1 hour. LCMS showed that the starting material peak was consumed and the desired peak was detected. Two additional vials were prepared as described above. All three reaction mixtures were combined and filtered, and the filtrate was purified by preparative HPLC to give 35 mg (12.95%) of compound 1 as a white solid. LCMS (ESI+): Rt = 1.304 min, m / z = 460.1 (M+H) + . 1 HNMR (400 MHz, DMSO- d 6 ) 11.92 (s, 1H), 8.72 (s, 1H), 8.09 (s, 1H), 7.13 (s,1H), 7.06 (br s, 1H), 4.71 (s, 2H), 3.39 (br d, J = 2.0 Hz, 2H), 3.15 (s, 3H), 2.90 (br dd, J = 6.3, 14.6 Hz, 4H), 2.81 (br t, J = 6.8 Hz, 2H).

[0214] Example 2 – Synthesis of 2-((4-chloro-5-((methanesulfonyl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (Compound 2) and 2-((2-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (Compound 3) Step 1. 3-Fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16Preparation of heptadec-1(10),2,4,6,11(16)-pentaen-12-one. 4-Chloro-3-fluoro-12-oxo-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 A solution of tert-butyl heptadecanoate-1(10),2,4,6,11(16)-pentaen-13-carboxylate (0.1 g, 1 equivalent, 255 µmol) in water (1 mL) and acetic acid (3 mL) was heated to 130 °C and stirred at 130 °C for 6 hours under microwave conditions. LCMS showed that the starting material was consumed and the desired peak was detected. Two additional vials were prepared as described above. After cooling to 20 °C, all three reaction mixtures were combined and concentrated under reduced pressure to give the residue. The residue was purified by preparative HPLC to give 45 mg (11.61%) of 3-fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0]. 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one, a white solid. LCMS (ESI+): Rt = 0.805 min, m / z 274.0 (M+H) + .

[0215] Step 2. Preparation of 2-((4-chloro-5-((methanesulfonyl)methyl)pyrimidin-2-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one and 2-((2-chloro-5-((methanesulfonyl)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one. To 3-fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16Heptadecyl-1(10),2,4,6,11(16)-pentaen-12-one (15 mg, 1 equivalent, 54.9 µmol) and 2,4-dichloro-5-(methanesulfonylmethyl)pyrimidine (13.2 mg, 1 equivalent, 54.9 µmol) in a solution of dimethyl sulfoxide (1.5 mL) were mixed with cesium carbonate (35.8 mg, 2 equivalent, 110 µmol) at 25 °C. The resulting mixture was stirred at 25 °C for 1 hour. LCMS showed that the starting material was consumed and two peaks with the desired mass were detected. Two additional vials were prepared as described above. All three reaction mixtures were combined and filtered. The filtrate was purified by preparative HPLC to give 2 mg (2.38%) of compound 2 as a pale yellow solid and 7 mg (7.95%) of compound 3. Compound 2: LCMS: Rt = 2.107 min, 89.33% purity, m / z = 477.9 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6 ) 11.66 (s, 1H), 8.79 - 8.75 (m, 1H), 8.00 (s, 1H), 7.12 (br s, 1H), 4.76 (s, 2H), 3.40 - 3.36 (m, 2H), 3.15 (s, 3H), 2.98 - 2.93 (m, 4H), 2.83 (t, J = 6.8 Hz, 2H). Compound 3: LCMS(ESI+): Rt = 1.159 min, 1.213 min, m / z 478.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6 )11.66 (s, 1H), 9.03 (s, 1H), 7.49 (s, 1H), 7.16 (br s, 1H), 4.86 - 4.43 (m,2H), 3.44 - 3.35 (m, 2H), 3.00 (s, 3H), 2.97 - 2.83 (m,4H), 2.79 - 2.63 (m,2H).

[0216] Example 3 – Synthesis of 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 6) Step 1. 3-Fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 Preparation of heptadec-1(10),2,4,6,11(16)-pentaen-12-one. To 4-chloro-3-fluoro-12-oxo-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 ]Tertibutyl heptadecyl-1(10),2,4,6,11(16)-pentane-13-carboxylic acid tert-butyl ester (0.2 g, 1 equivalent, 510 µmol) was added at 25 °C to a solution of dioxane (2 mL) and water (2 mL) with the addition of bis(tert-butyl)[2',4',6'-tris(isopropyl)-2-biphenyl]phosphine (65 mg, 0.3 equivalent, 153 µmol) and palladium-(1 E 4 E 1,5-Diphenyl-1,4-pentadien-3-one (2 / 3) (140 mg, 0.3 equivalents, 153 µmol) and potassium hydroxide (286 mg, 10 equivalents, 5.1 mmol). The reaction mixture was heated to 90 °C and stirred at 90 °C for 0.5 h. LCMS showed that the starting material was consumed and the desired mass was detected. Three additional vials were prepared as described above. After cooling to 20 °C, all four reaction mixtures were combined, diluted with water (20 mL), and extracted with ethyl acetate (10 mL). A solid formed in the aqueous phase, and the aqueous phase was filtered. The filter cake was dried under reduced pressure to give the residue. The residue was milled with ethyl acetate (30 mL) and filtered. The filter cake was dried under reduced pressure to give 220 mg (39.43%) of 3-fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0]. 2 , 7 .0 11 , 16 [Heptadec-1(10),2,4,6,11(16)-pentaen-12-one, a gray solid. LCMS (ESI+): Rt = 0.220 min, m / z 274.0 (M+H)+ .

[0217] Step 2. 2-Chloro-4-((1-Fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5- H -pyrido[3',4':4,5]pyrrolo[2,3- f [Isoquinoline-2-yl)oxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5] H Preparation of tert-butyl formate. To 3-fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 Heptadecyl-1(10),2(7),3,5,11(16)-pentaen-12-one (90 mg, 1 equivalent, 329 µmol) was added to a solution of dimethyl sulfoxide (1 mL) at 25 °C with tert-butyl 2,4-dichloro-5,6,7,8-tetrahydro-1,3,6-triaza-6-naphthoate (130 mg, 1.3 equivalent, 428 µmol) and potassium carbonate (137 mg, 3 equivalent, 988 µmol). The reaction mixture was heated to 30 °C and stirred at 30 °C for 4 hours. LCMS showed that the starting material was consumed and two peaks with the desired mass were detected. After cooling to 25 °C, all three reaction mixtures were combined, diluted with water (20 mL), and extracted with ethyl acetate (3 × 15 mL). The organic phases were combined, washed with brine (30 mL), and dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate = 100 / 1 to 5 / 1) to give 250 mg of crude product, which was further purified by preparative HPLC to give 30 mg of 2-chloro-4-((1-fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5-) H -pyrido[3',4':4,5]pyrrolo[2,3- f [Isoquinoline-2-yl)oxy)-7,8-dihydropyrido[4,3-] d ]Pyrimidine-6(5 H tert-butyl formate, a white solid. LCMS (ESI+): Rt = 0.651 min, 0.710 min, m / z 541.0 (M+H) + .

[0218] Step 3. 2-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-) d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7 H -pyrido[3',4':4,5]pyrrolo[2,3- f Preparation of isoquinoline-7-one. 2-chloro-4-((1-fluoro-7-oxo-6,7,8,9,10,11-hexahydro-5-) was added to dichloromethane (2 mL). H -pyrido[3',4':4,5]pyrrolo[2,3- f [Isoquinoline-2-yl)oxy)-7,8-dihydropyrido[4,3-] d ]Pyrimidine-6(5 H 0.2 g (1 equivalent, 370 µmol) of tert-butyl formate was added to trifluoroacetic acid (0.2 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 1 hour. LC-MS showed that the starting material was consumed and the desired peak was detected. The reaction mixture was concentrated under reduced pressure to give 200 mg (crude) of 2-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-) d ]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7 H -pyrido[3',4':4,5]pyrrolo[2,3- f Isoquinoline-7-one, a yellow oily substance. LCMS (ESI+): Rt = 0.293 min, m / z 441.0 (M+H) + .

[0219] Step 4. Preparation of 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridano[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridano[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one. 2-((2-chloro-5,6,7,8-tetrahydropyridano[4,3-)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyridano[3',4':4,5]pyrrolo[2 ... d ]pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7 H -pyrido[3',4':4,5]pyrrolo[2,3- fIsoquinoline-7-one (0.2 g, crude) was reacted with 37% (w / w) formaldehyde (44.2 mg, 1.2 equivalents, 544 µmol) and sodium cyanoborohydride (57 mg, 2 equivalents, 907 µmol) at 25 °C. The reaction mixture was stirred at 25 °C for 1 hour. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give 55 mg of compound 6 as a white solid. LCMS (ESI+): Rt = 0.373 min, 0.412 min, m / z 455.0 (M+H) + . 1 H NMR (400 MHz, CDCl3) 9.03 (br dd, J = 1.9, 8.3 Hz, 1H),7.89 (s, 1H), 5.37 (br s, 1H), 3.72 (s, 2H), 3.66 - 3.59 (m, 2H), 3.21 - 3.14(m, 2H), 3.07 - 3.01 (m, 2H), 3.01 - 2.90 (m, 4H), 2.85 (t, J = 5.8 Hz, 2H), 2.57 (s, 3H).

[0220] Example 4 – 2-((2-chloro-5-fluoropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7 - Synthesis of ketone (compound 4) Step 1. 4-(2-chloro-5-fluoro-4-pyrimidinylamino)-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 Preparation of tert-butyl 1-(10),2(7),3,5,11(16)-pentaen-13-carboxylic acid. To 4-chloro-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16tert-butyl heptadecyl-1(10),2,4,6,11(16)-pentane-13-carboxylate (0.2 g, 383 µmol) was added under nitrogen at 20 °C to a solution of 1,4-dioxane (4 mL, 46.9 mmol). 2-chloro-5-fluoro-4-pyrimidinamine (56.5 mg, 383 µmol), cesium dicarbonate (374 mg, 3 equivalents, 1.15 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyl-9H-xanthones (44.3 mg, 0.2 equivalents, 76.6 µmol) and palladium-(1E,4E)-1,5-diphenyl-1,4-pentadien-3-one (2 / 3) (70.2 mg, 0.2 equivalents, 76.6 µmol) were added to the mixture. The mixture was heated to 100 °C and stirred at 100 °C for 12 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. Four vials were prepared as described above. After cooling to 20°C, all five reaction mixtures were combined, diluted with water (50 mL), and extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with brine (50 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate = 100 / 0 to 0 / 1) to obtain 4-(2-chloro-5-fluoro-4-pyrimidinylamino)-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [110 mg, 139 µmol] Tert-butyl heptadecyl-1(10),2(7),3,5,11(16)-pentane-13-carboxylate, a yellow solid. LCMS (ESI+): R t = 0.472 min, m / z 503.1 / 505.1 (M+H) + .

[0221] Step 2.2 Preparation of 4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one. 2 , 7 .0 11 , 16A solution of heptadecyl-1(10),2(7),3,5,11(16)-pentane-13-carboxylic acid tert-butyl ester (110 mg, 0.57 equivalents, 219 µmol) in dichloromethane (5 mL, 78.1 mmol) and trifluoroacetic acid (0.5 mL) was stirred at 20 °C for 1 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give the residue, which was then subjected to preparative HPLC (neutral conditions: column: Waters Xbridge BEH C18 100). × 30 mm × 10 µm; mobile phase: [A: water (10 mM ammonium bicarbonate); B: acetonitrile]; B%: 15.00% - 45.00%, 8.00 min) purified to give compound 4 (25.7 mg, 60.7 µmol), as a yellow solid. LCMS (ESI+): R t = 1.168 min, m / z 403.1 / 405.0 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ11.58 (s, 1H), 10.50 (br d, J = 5.8 Hz, 1H), 8.41 (d, J = 3.1 Hz, 1H), 8.07 (s,1H), 7.10 (br s, 1H), 3.40 - 3.37 (m, 2H), 2.98 - 2.88 (m, 4H), 2.84 (t, J =6.8 Hz, 2H).

[0222] Example 5 – Synthesis of 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 5) Step 1. 4-(2-chloro-4-pyrimidinylamino)-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16Preparation of tert-butyl 1-(10),2(7),3,5,11(16)-pentaen-13-carboxylic acid. To 4-chloro-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [A solution of heptadec-1(10),2,4,6,11(16)-pentane-13-carboxylic acid tert-butyl ester (0.2 g, 383 µmol) in 1,4-dioxane (4 mL, 46.9 mmol) was added under nitrogen at 20 °C to a solution of 2-chloro-4-pyrimidinamine (49.6 mg, 383 µmol), cesium dicarbonate (374 mg, 3 equivalents, 1.15 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethyl-9 H -Xanton (44.3 mg, 0.2 equivalent, 76.6 µmol) and palladium-(1 E 4 E 1,5-Diphenyl-1,4-pentadien-3-one (2 / 3) (70.2 mg, 0.2 equivalents, 76.6 µmol). The mixture was heated to 100 °C and stirred at 100 °C for 12 hours. LCMS showed that the starting material was completely consumed and the desired mass was detected. Four vials were prepared as described above. After cooling to 20 °C, all five reaction mixtures were combined, diluted with water (50 mL), and extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with brine (50 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was then purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate = 100 / 0 to 0 / 1) to obtain 4-(2-chloro-4-pyrimidinylamino)-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [130 mg, 194 µmol] tert-butyl heptadecyl-1(10),2(7),3,5,11(16)-pentane-13-carboxylate, a yellow solid. LCMS (ESI+): R t = 0.512 min, m / z 485.1 / 487.1 (M+H) + .

[0223] Step 2.2 Preparation of 4-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one. 2 , 7 .0 11 , 16 A solution of heptadecano-1(10),2(7),3,5,11(16)-pentaen-13-carboxylic acid tert-butyl ester (130 mg, 268 µmol) in trifluoroacetic acid (0.5 mL) and dichloromethane (5 mL) was stirred at 20 °C for 1.5 h. LCMS showed that the starting material was consumed and the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give the residue, which was purified by preparative HPLC to give compound 5 (10.3 mg, 25.4 µmol) as a white solid. LCMS (ESI+): R t = 1.284 min, m / z 385.1 / 387.0 (M+H) + . 1 H NMR (400 MHz, DMSO- d 6 )δ 11.60 (s, 1H), 10.46 - 10.30 (m, 1H), 8.31 (d, J = 5.9 Hz, 1H), 8.00 (s, 1H), 7.53 (d, J = 5.9 Hz, 1H), 7.09 (s, 1H), 3.40 - 3.36 (m, 2H), 2.96 - 2.90 (m, 2H), 2.90 - 2.82 (m, 4H). Example 6 – 2-chloro-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8 H -pyrido[3',4':4,5]pyrrolo[2,3- f Synthesis of tert-butyl isoquinoline-8-carboxylate (intermediate 1) Step 1. Preparation of 5-allyl-2-chloro-3-fluoroisononal. Tert-butyllithium (5.1 g, 1.3 M, 79.85 mmol) was added dropwise to a solution of 2-chloro-3-fluoropyridine (10 g, 76.05 mmol) in tetrahydrofuran (250 mL) at -78 °C for 15 min. After stirring for 1 hour, the tert-butyllithium was slowly added... N-[2-(dimethylamino)ethyl]- N 10.4 g (79.85 mmol) of methylformamide was added, and the reaction mixture was heated to -40 °C and stirred for another 10 minutes. Next, 7.3 g (1.6 M, 114.05 mmol) of n-butyllithium was added to the reaction mixture. The reddish-brown solution was stirred at -30 °C for 3 hours, and then copper(I) bromide (14.2 g, 98.85 mmol) was added. The reaction mixture was brought to 0 °C and stirred at that temperature for 1 hour. After cooling back to -30 °C, a solution of allyl bromide (14.7 g, 121.65 mmol) in tetrahydrofuran (150 mL) was added. The reaction mixture was stirred at -10 °C for 1 hour. TLC (petroleum ether:ethyl acetate = 5:1, R f = 0.72) indicates that the starting material was consumed and a new spot was formed. The mixture was quenched with saturated ammonium chloride (300 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to give the residue, which was purified by rapid silica gel chromatography (ISCO®; 120 g SepaFlash® silica gel column, eluent 0–10% ethyl acetate / petroleum ether gradient @ 200 mL / min) to give 5-allyl-2-chloro-3-fluoroisononical (4.8 g, 32% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO- d 6) δ = 3.73 (br d, J = 6.13 Hz, 2 H)5.02 - 5.11 (m, 2 H) 5.92 - 6.05 (m, 1 H) 8.33 (s, 1 H) 10.32 (s, 1 H).

[0224] Step 2. Preparation of 1-(5-allyl-2-chloro-3-fluoropyridin-4-yl)prop-2-en-1-ol. Vinyl magnesium bromide (28.2 g, 1 M, 215 mmol) was added to a solution of 5-allyl-2-chloro-3-fluoroisononiaaldehyde (28 g, 140 mmol) in tetrahydrofuran (400 mL) at 0 °C for 10 minutes. The mixture was stirred at 0 °C for 2 hours. LCMS showed that the starting material was consumed and a new peak with the desired mass was detected. The mixture was quenched with saturated ammonium chloride (1000 mL) and extracted with ethyl acetate (3 × 500 mL). The organic phase was washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to give the residue, which was then purified by rapid silica gel chromatography (ISCO®; 80 g SepaFlash® silica gel column, eluent 0–15% ethyl acetate / petroleum ether gradient @ 200 mL / min) to give 1-(5-allyl-2-chloro-3-fluoropyridin-4-yl)prop-2-en-1-ol (16.8 g, yield 39.45%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δppm 2.62 (br s, 1 H) 3.33 - 3.70 (m, 2 H) 5.02 (br d, J =17.01 Hz, 1 H) 5.16(br d, J =10.01 Hz, 1 H) 5.22 - 5.44 (m, 2 H) 5.56 (br d, J =4.63 Hz, 1 H) 5.95(ddt, J =16.76, 10.51, 6.00, 6.00 Hz, 1 H) 6.03 - 6.21 (m, 1 H) 8.02 (s, 1 H).

[0225] Step 3. Preparation of 3-chloro-4-fluoro-5,8-dihydroisoquinoline-5-ol. Benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidine-2-ylidene]-dichloro-ruthenium; tricyclohexylphosphine (578.01 mg, 680.83 μmol) was added to a solution of 1-(5-allyl-2-chloro-3-fluoropyridin-4-yl)prop-2-en-1-ol (3.1 g, 13.62 mmol) in dichloromethane (140 mL). The mixture was stirred at 15 °C for 3 hours. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The mixture was filtered and concentrated under vacuum to give the residue, which was then purified by rapid silica gel chromatography (ISCO®; 200 g SepaFlash® silica gel column, eluent 0–15% petroleum ether gradient / ethyl acetate @ 200 mL / min) to give 3-chloro-4-fluoro-5,8-dihydroisoquinoline-5-ol (2.3 g, yield 84.62%) as a green solid. 1 H NMR (400 MHz, CDCl3) δ ppm 2.57 (br d, J =5.75 Hz, 1 H) 3.31 - 3.60 (m, 2 H) 5.47 (br s, 1 H) 6.06 - 6.16 (m, 1 H) 6.17 - 6.26 (m, 1 H) 8.12 (s, 1 H).

[0226] Step 4. Preparation of 3-chloro-4-fluoro-5,6,7,8-tetrahydroisoquinoline-5-ol. Platinum dioxide (1.32 g, 5.81 mmol) was added to a solution of 3-chloro-4-fluoro-5,8-dihydroisoquinoline-5-ol (13.2 g, 66.1 mmol) in methanol (400 mL). The mixture was stirred at 15 °C under a hydrogen atmosphere (balloon) (15 Psi) for 2 hours. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The mixture was filtered and washed with methanol (50 mL). The filtrate was concentrated under vacuum to give the residue, which was then subjected to column chromatography (SiO2, petroleum ether:ethyl acetate = 1:0 to 5:1, TLC showed R... f Purification was performed using a solution of 0.55 (PE:EA = 2:1) to give 3-chloro-4-fluoro-5,6,7,8-tetrahydroisoquinoline-5-ol (9.5 g, yield 64.13%) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 1.69 - 1.97 (m, 4 H) 1.98- 2.05 (m, 1 H) 2.27 (br s, 1 H) 2.53 - 2.65 (m, 1 H) 2.75 - 2.86 (m, 1 H)5.03 (br d, J =3.63 Hz, 1 H) 7.96 (s, 1 H).

[0227] Step 5. 3-Chloro-4-fluoro-7,8-dihydroisoquinoline-5(6) H Preparation of 5-ketones. Oxaloyl chloride (969.45 mg, 7.64 mmol) in dichloromethane (20 mL) was added to a solution of dimethyl sulfoxide (1.09 g, 13.90 mmol) at -60 °C. After stirring for 5 min at -60 °C, a solution of 3-chloro-4-fluoro-5,6,7,8-tetrahydroisoquinoline-5-ol (1.4 g, 6.94 mmol) in dichloromethane (20 mL) was added dropwise to the mixture over 3 min, and the mixture was stirred for another 15 min. Triethylamine (3.51 g, 34.72 mmol) was added, and the mixture was stirred at -60 °C for 5 min. The resulting mixture was heated to 20 °C and stirred for 2.5 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The mixture was poured into ice water (30 mL) and extracted with dichloromethane (3 × 20 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to give the residue, which was then ground with n-heptane (30 mL) at 0 °C and filtered. The filter cake was dried under vacuum to give 3-chloro-4-fluoro-7,8-dihydroisoquinoline-5 (6... H )-ketone (1.2 g, yield 87%), is a white solid. 1 H NMR (400 MHz, CDCl3) δ ppm2.19 (quin, J =6.38 Hz, 2 H) 2.68 - 2.77 (m, 2 H) 2.99 (t, J =6.13 Hz, 2 H) 8.26(s, 1 H).

[0228] Step 6.6-Bromo-3-chloro-4-fluoro-7,8-dihydroisoquinoline-5(6) HPreparation of 3-chloro-4-fluoro-7,8-dihydroisoquinoline-5 (6-hydroxymethyl 5-ethylhexyl ester) was prepared by adding bromine (8.6 g, 43.1 mmol) in acetic acid (100 mL) dropwise to a solution of bromine (8.6 g, 43.1 mmol) in acetic acid (100 mL) at 15 °C to hydrobromic acid (40 mL, 37% acetic acid solution). H )-ketone (3.4 g, 43.1 mmol). Next, the mixture was stirred at 35 °C for 15 min. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The reaction mixture was basified to pH = 8 with saturated sodium carbonate and extracted with ethyl acetate (3 × 200 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 6-bromo-3-chloro-4-fluoro-7,8-dihydroisoquinoline-5 (6 H )-ketone (8 g, yield 66.67%), a white solid, was used in the next step without purification. 1 H NMR (400 MHz, CDCl3) δ ppm 2.51 - 2.58 (m, 2 H) 2.97 - 3.05 (m, 1 H) 3.31 (br d, J =10.26 Hz, 1 H) 4.69 (t, J =3.75 Hz, 1 H) 8.29 (s, 1 H).

[0229] Step 7. 2-Chloro-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8 H -pyrido[3',4':4,5]pyrrolo[2,3- f Preparation of tert-butyl isoquinoline-8-carboxylate. To 6-bromo-3-chloro-4-fluoro-7,8-dihydroisoquinoline-5(6... H 2,4-dioxopiperidin-1-carboxylic acid tert-butyl ester (8.58 g, 40.2 mmol) and ammonium acetate (6.64 g, 86.2 mmol) were added to a solution of 2,4-dioxopiperidin-1-carboxylic acid tert-butyl ester in methanol (35 mL). The mixture was stirred at 15 °C for 2 h and then heated to 70 °C for another 2 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The reaction mixture was concentrated under vacuum to give a crude product, which was then milled with dichloromethane (50 mL) to give 2-chloro-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8-dioxopiperidin-1-carboxylic acid tert-butyl ester (8.58 g, 40.2 mmol) and ammonium acetate (6.64 g, 86.2 mmol). H -pyrido[3',4':4,5]pyrrolo[2,3- fIsoquinoline-8-carboxylic acid tert-butyl ester (intermediate 1) (4.3 g, yield 38.2%), as a white solid. LCMS: RT = 2.534 min, 98.2% purity. m / z = 392.1 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.47 (s, 9 H) 2.91 (br d, J =6.75 Hz, 2 H)2.93 - 3.06 (m, 4 H) 3.95 (t, J =6.32 Hz, 2 H) 5.76 (s, 1 H) 8.07 (s, 1 H)11.54 - 12.33 (m, 1 H).

[0230] Example 7 – 2-Chloro-7-oxo-5,6,7,9,10,11-hexahydro-8 H Synthesis of -pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid tert-butyl ester (intermediate 2) Step 1. Preparation of 3-chloro-5,6,7,8-tetrahydroisoquinoline. Platinum dioxide (3 g, 60.05 mmol) was added to a solution of 3-chloroisoquinoline (25 g, 30.56 mmol) in trifluoroacetic acid (250 mL) and trifluoromethanesulfonic acid (75 mL). The mixture was stirred at 30 °C for 15 hours under a hydrogen atmosphere (15 psi). TLC (petroleum ether:ethyl acetate = 5:1, R f =0.6) indicates that the starting material was completely consumed and formed a major spot. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the residue, which was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 100:1 to 5:1) to give 3-chloro-5,6,7,8-tetrahydroisoquinoline (10.5 g, yield 41%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) 1.65 - 1.80 (m, 4 H) 2.59 - 2.73 (m, 4 H) 8.00 (s, 1 H).

[0231] Step 2. E )-3-chloro-7,8-dihydroisoquinoline-5(6) HPreparation of 3-ketooximes. Potassium tert-butoxide (20.78 g, 185.20 mmol) in tetrahydrofuran (200 mL) was added to a solution of 3-chloro-5,6,7,8-tetrahydroisoquinoline (10.3 g, 61.73 mmol) in tetrahydrofuran (100 mL). After stirring at 15 °C for 4 hours, tert-butyl nitrite (12.73 g, 123.47 mmol) was added to the reaction mixture at 0 °C. The resulting mixture was stirred at 15 °C for 2 hours. LCMS showed that the starting material was consumed and two new peaks with the desired mass were detected. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give the residue, which was then crystallized from dichloromethane (100 mL) at 20 °C to give ( E )-3-chloro-7,8-dihydroisoquinoline-5(6) H )-ketooxime (11 g, yield 91%), is a brown solid. 1 H NMR (400 MHz, DMSO- d 6) 1.83 (m, 2 H)1.95 (m, 1 H) 2.58 - 2.62 (m, 1 H) 2.72 (t, J =6.63 Hz, 2 H) 2.78 (t, J =6.00 Hz, 2 H) 2.89 (t, J =6.19 Hz, 1 H) 7.74 (s, 1 H) 8.35 (s, 1 H) 8.44 (s, 1 H) 8.69 (s, 1 H).

[0232] Step 3.3-Chloro-7,8-dihydroisoquinoline-5(6) H Preparation of )-ketones. To ( E )-3-chloro-7,8-dihydroisoquinoline-5(6) H 3-Chloro-7,8-dihydroisoquinoline-5 (6 mmol) was added to a solution of acetone (120 mL) with hydrochloric acid (100 mL, 2.84 mol). The mixture was stirred at 60 °C for 3 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The reaction mixture was quenched with an aqueous sodium carbonate solution (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was purified by reversed-phase HPLC (0.1% HCl) to give 3-chloro-7,8-dihydroisoquinoline-5 (6 mmol). H )-ketone (8.1 g, yield 79.72%), in brown solid form. 1H NMR (400 MHz, DMSO- d 6) 2.21 (m, 2 H) 2.68 -2.78 (m, 2 H) 2.98 (t, J =6.13 Hz, 2 H) 7.82 (s, 1 H) 8.47 (s, 1 H).

[0233] Step 4.6-Bromo-3-chloro-7,8-dihydroisoquinoline-5(6) H Preparation of 3-chloro-7,8-dihydroisoquinoline-5(6-)-one. H 6-Bromo-3-chloro-7,8-dihydroisoquinoline-5 (6 mmol) was added to a solution of bromine (7.04 g, 44.05 mol) in hydrobromic acid (80 mL) at 0 °C. The mixture was stirred at 20 °C for 2 h. LCMS showed approximately 7% of the starting material remaining and detected a main peak with the desired mass. The mixture was quenched with an aqueous sodium carbonate solution (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 6-bromo-3-chloro-7,8-dihydroisoquinoline-5 (6 mmol) H )-ketone (7.36 g, crude product), a brown solid. 1 H NMR (400 MHz, DMSO-) d 6) 2.46 (m, 2 H) 2.89 (m, 1 H) 3.15 - 3.27 (m, 1 H) 4.68 (t, J =3.88 Hz, 1 H) 7.82 (s, 1 H) 8.43 (s, 1 H).

[0234] Step 5.2 - Chloro-7-oxo-5,6,7,9,10,11-hexahydro-8 H -pyrido[3',4':4,5]pyrrolo[2,3- f Preparation of tert-butyl isoquinoline-8-carboxylate. To 6-bromo-3-chloro-7,8-dihydroisoquinoline-5(6... H7.2 g (23.49 mmol) of 2,4-dioxopiperidine-1-carboxylic acid tert-butyl ester (6.01 g, 28.19 mmol) and ammonium acetate (5.43 g, 70.438 mmol) were added to a solution of 2,4-dioxopiperidine-1-carboxylic acid in 80 mL of methanol. After stirring at 20 °C for 2 hours, the mixture was heated to 80 °C and held at 80 °C for 14 hours. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The mixture was treated with water (150 mL) and extracted with ethyl acetate (3 × 80 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was then purified by preparative HPLC (column: Phenomenex Gemini-NX80 × 40 mm × 3 mm; mobile phase: [H2O (10 mM NH4HCO3)-ACN]; gradient: 25%-50% B, duration: 10.0 min) to give 2-chloro-7-oxo-5,6,7,9,10,11-hexahydro-8 H -pyrido[3',4':4,5]pyrrolo[2,3- f Isoquinoline-8-carboxylic acid tert-butyl ester (intermediate 2) (2.8 g, yield 31.88%), is a gray solid. 1 H NMR (400 MHz, DMSO- d 6) 1.47 (s, 9 H) 2.86 (br d, J =7.25 Hz, 2 H) 2.88- 2.99 (m, 4 H) 3.96 (t, J =6.25 Hz, 2 H) 7.42 (s, 1 H) 8.15 (s, 1 H) 12.18 (brs, 1 H).

[0235] Example 8 – General Procedure A: Synthesis of (S)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridano[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridano[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one and (R)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridano[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridano[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compounds 75 and 76).

[0236] Example 1_1: 5-methyl-2,4-dioxo-1-piperidinecarboxylate tert-butyl ester (171 g, 1.2 equivalents, 754 mmol) and ammonium acetate (145 g, 3 equivalents, 1.89 mol) were added to a solution of 6-bromo-3-chloro-4-fluoro-7,8-dihydro-5(6H)-isoquinolinone (175 g, 628 mmol) in methanol (1.75 L, 43.2 mol) at 25 °C. The reaction mixture was stirred at 80 °C for 3 h. LCMS showed that the starting material was consumed and a peak with the desired mass was detected. The reaction mixture was concentrated to remove 2 / 3 of the methanol and then poured into ice water (3 L). The solid was obtained by filtration, washed with petroleum ether, and dried to give a crude product. The crude product was ground with petroleum ether:methyl tert-butyl ether = 10:1 for 10 h. The mixture was filtered and concentrated to dryness to give tert-butyl 2-chloro-1-fluoro-10-methyl-7-oxo-5,6,7,9,10,11-hexahydro-8H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid (251 g, 519 mmol, 82.68% yield) as a brown solid.

[0237] Example 1_2 : The compound 2-chloro-1-fluoro-10-methyl-7-oxo-5,6,7,9,10,11-hexahydro-8H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid tert-butyl ester (249 g, 614 mmol) was dissolved in hydrogen chloride (2.49 L, 4 M) in ethyl acetate. The resulting mixture was stirred at 25 °C for 1 h. LC-MS showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to give the residue, which was then milled at 25 °C with 1,4-dioxane (5 volumes) for 2 h. After filtration, the solid was concentrated under reduced pressure to give 2-chloro-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (190 g, 532 mmol, 86.79% yield), as a yellow solid.

[0238] Example 1_3 :The solution of 2-chloro-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (60 g, 196 mmol) in 1,4-dioxane (0.6 L, 7.03 mol) was added at 25 °C to a solution of potassium hydroxide (55.1 g, 5 equivalents, 981 mmol), di-tert-butyl(2',4',6'-triisopropyl-2-biphenyl)phosphine (25 g, 0.3 equivalents, 58.9 mmol), and (1E,4E)-1,5-diphenyl-1,4-pentadien-3-one-1,5-diphenyl-1,4-pentadien-3-one-palladium (1 / 2 / 2) (18) in water (0.3 L, 16.7 mol). The resulting mixture was then stirred at 90 °C for 2 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. Two additional vials were prepared as described above. All three reactions were combined and filtered. The pad was washed with ethyl acetate (800 mL). The aqueous phase was washed with ethyl acetate (800 mL × 3) and adjusted to pH 3–4 with solid citric acid at 0 °C. The mixture was filtered and the filter cake was washed with water (300 mL × 3) and dried under vacuum to give 1-fluoro-2-hydroxy-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (145 g, 505 mmol, 91.13% yield) as a yellow solid.

[0239] Example 1_4 :To a solution of 1-fluoro-2-hydroxy-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (31 g, 108 mmol) in dimethyl sulfoxide (620 mL, 8.66 mol), Ag₂CO₃ (149 g, 5 equivalents, 540 mmol) and tert-butyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-formate (49.2 g, 1.5 equivalents, 162 mmol) were added at 25 °C. The resulting mixture was then stirred at 80 °C for 16 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. Two additional vials were prepared as described above. All three reactions were combined, diluted with methanol (4 L), and stirred at 25 °C for 0.5 h. The resulting mixture was then filtered through a diatomaceous earth mat, which was washed with methanol (300 mL × 3). The filtrate was concentrated, poured into ice water (8 L), and extracted with dichloromethane (2 L × 4). The organic layers were combined and dried over sodium sulfate, filtered, and concentrated to give the residue, which was purified by silica gel column chromatography (petroleum ether / dichloromethane = 1:0 to 0:1, followed by dichloromethane / ethyl acetate = 1:0 to 4:1) to give tert-butyl 2-chloro-4-((1-fluoro-10-methyl-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)oxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylic acid (53 g, 79.3 mmol, 24.48%) as a yellow solid.

[0240] Example 1_5 :To a solution of 2-chloro-4-((1-fluoro-10-methyl-7-oxo-6,7,8,9,10,11-hexahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-2-yl)oxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester (40 g, 1 equivalent, 72.1 mmol) in dichloromethane (0.8 L, 12.5 mol), trimethyl(trifluoromethanesulfonyloxy)silane (80.1 g, 5 equivalent, 360 mmol) and 2,6-dimethylpyridine (42 mL, 5 equivalent, 360 mmol) were added at 0 °C. The mixture was stirred at 0 °C for 0.5 h. LCMS showed that the starting material was consumed and a main peak with the desired mass was detected. The reaction mixture was concentrated under reduced pressure to give 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (32.8 g, 72.1 mmol, crude), as a yellow oil.

[0241] Examples 1-6: Formaldehyde (29.3 g, 5 equivalents, 361 mmol) and sodium cyanoborohydride (9.06 g, 2 equivalents, 144 mmol) were added to a solution of 2-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (32.8 g, 1 equivalent, 72.1 mmol) in methanol (0.2 L, 4.94 mol) at 0 °C. The mixture was stirred at 0 °C for 1 h. LCMS showed that the starting material was completely consumed and the desired mass was detected. The reaction mixture was poured into ice-saturated aqueous solution of NaHCO3 (1 L) and extracted with dichloromethane (500 ml × 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluting with petroleum ether:ethyl acetate = 1:0 to 0:1 to dichloromethane:methanol = 1:0 to 9:1 to 1:1) to give 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (28 g, 53.7 mmol), as a yellow solid.

[0242] Compounds 75 and 76: 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (20 g, 42.7 mmol) was prepared by a preparative SFC (column: ChiralPak IH, 250*50 mm, 10 μm; mobile phase: [A: CO2; B: IPA (0.1% NH3H2O)]; B%: 60.00%-60.00%, 18.00 min; flow rate: 180.00 min). Purification at (g / min) yielded (R) or (S)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (8.604 g, 18 g / min). mmol, 97.9% purity), as a pale yellow solid, and (S) or (R)-2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (8.23 g, 17.1 mmol), as a white solid.

[0243] The compounds in Table S-1 were synthesized using general procedure A. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0244] Table S-1.

[0245] Example 9 – General Procedure B: Synthesis of 2'-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-5',6',8',9'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(11'H)-one (compound 145).

[0246] Example 2_1: Cesium carbonate (24.6 g, 5 equivalents, 75.5 mmol) and (2-chloromethoxyethyl)tris(methyl)silane (8.02 mL, 3 equivalents, 45.3 mmol) were added to a solution of 2'-chloro-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (4.8 g, 1 equivalent, 15.1 mmol) in dimethylformamide (50 mL) at 25 °C. The mixture was stirred at 80 °C for 3 h and monitored by LCMS. The mixture was quenched with water (50 mL) and extracted with ethyl acetate (100 mL × 3). The organic phases were then combined and concentrated under reduced pressure to give the residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate = 100:1 to 4 / 6) to give 2'-chloro-1'-fluoro-11'-((2-(trimethylsilyl)ethoxy)methyl)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (5 g, 11.2 mmol, 73.8% yield) as a white solid.

[0247] Example 2_2: To a solution of 2'-chloro-1'-fluoro-11'-((2-(trimethylsilyl)ethoxy)methyl)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (2.5 g, 1 equivalent, 5.58 mmol) in tetrahydrofuran (25 mL), n-butyllithium (2.5 M, 3.35 mL, 1.5 equivalent, 8.37 mmol) was added at -78 °C, and the mixture was stirred at -78 °C for 10 min. Tert-butoxycarbonyl-tert-butyl carbonate (1.92 mL, 1.5 equivalent, 8.37 mmol) was added to the above mixture, and the mixture was stirred at 0 °C for 1 h. The mixture was quenched with water (15 mL) and extracted with ethyl acetate (15 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate = 100 / 0 to 9 / 1) to give 2'-chloro-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-tert-butyl formate (2.5 g, 4.55 mmol, 81.73% yield), as a white solid. LCMS: Rt: 0.715 min; [M+H] + = 548.3. 1 H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 5.19 (s, 2H), 3.80 (s, 2H), 3.29 - 3.20 (m, 2H), 3.08- 3.00 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H), 1.58 (s, 9H), 1.56 - 1.52 (m, 2H), 1.14 - 1.08 (m, 2H), 0.83 - 0.76 (m, 2H), -0.07 (s, 9H).

[0248] Example 2_3: To a solution of 2'-chloro-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylic acid tert-butyl ester (2.5 g, 1 equivalent, 4.56 mmol) in 1,4-dioxane (50 mL), diphenylimine (992 mg, 1.2 equivalent, 5.47 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethyl-9H-xanthones (1.32 g, 0.5 equivalent, 2.28 mmol) were added at 25°C. The mixture contained 2.09 g (2 equivalents, 2.28 mmol) of (1E,4E)-1,5-diphenyl-1,4-pentadien-3-one-1,5-diphenyl-1,4-pentadien-3-one-palladium (1 / 2 / 2) and cesium carbonate (2.97 g, 2 equivalents, 9.12 mmol). After heating to 100 °C, the mixture was stirred at 100 °C for 4 h under a nitrogen atmosphere, and then monitored by LCMS. The mixture was quenched with water (50 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the residue, which was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 1 / 3) to give 2'-((diphenylmethylene)amino)-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-tert-butyl formate (1.5 g, 2.16 mmol, 47.46% yield), as a yellow solid.

[0249] Example 2_4: Hydrogen chloride (5 M, 4.33 mL, 10 equivalents, 21.6 mmol) was added to a solution of 2'-((diphenylmethylene)amino)-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-tert-butyl formate (1.5 g, 1 equivalent, 2.16 mmol) in tetrahydrofuran (15 mL) at 0 °C. The mixture was stirred at 25 °C for 2 h and monitored by LCMS. The mixture was quenched with saturated sodium bicarbonate and the pH was adjusted to 8. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the residue, which was then analyzed by preparative TLC (petroleum ether / ethyl acetate = 1 / 1, R...). f= 0.5) purified to give tert-butyl 2'-amino-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylic acid, as a yellow solid.

[0250] Example 2_5: Tert-butyl 2,4-dichloro-5,6,7,8-tetrahydro-1,10'-pyrido-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylate (0.5 g, 1 equivalent, 946 µmol) in 1,4-dioxane (5 mL) was added at 25°C to a solution of 2'-amino-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylate (575 mg, 2 equivalent, 1.89 mmol) and cesium dicarbonate (924 mg, 3 equivalent, 2.84 mmol) in 1,4-dioxane (5 mL). 189 µmol of 4,5-bis(diphenylphosphino)-9,9-dimethyl-9H-xanthones (109 mg, 0.2 equivalents, 189 µmol) and (1E,4E)-1,5-diphenyl-1,4-pentadien-3-one-1,5-diphenyl-1,4-pentadien-3-one-palladium (1 / 2 / 2) (86.6 mg, 0.1 equivalents, 94.6 µmol). After purging and degassing with nitrogen three times, the mixture was stirred at 100 °C for 12 h under a nitrogen atmosphere and monitored by LCMS. After cooling to 25 °C, the mixture was quenched with water (5 mL) and extracted with ethyl acetate (5 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the residue, which was then passed through a preparative HPLC system (column: Waters Xbridge BEH C18 250 x 50 mm x 10 μm; mobile phase: [A: water (10 mM NH4HCO3); B: acetonitrile]; B%: 65.00%–90.00%, 10.00 min; flow rate: 60.00 min). Purification was performed at a rate of mL / min to give tert-butyl 2'-((6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylic acid (130 mg, 0.16 mmol, yield 17.26%).

[0251] Example 2_6: 110 mg, 1 equivalent, 138 µmol of tert-butyl tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-7'-oxo-11'-((2-(trimethylsilyl)ethoxy)methyl)-5',6',7',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-8'(9'H)-carboxylic acid tert-butyl ester (2.2 mL) in dichloromethane was added to a solution at 0 °C with 162 µL, 10 equivalent, 1.38 mmol of tin tetrachloride. The reaction mixture was heated to 25 °C and stirred at 25 °C for 3 h, and then monitored by LCMS. The mixture was quenched with sodium bicarbonate solution and the pH was adjusted to 9, followed by extraction with ethyl acetate (2 mL × 3). The organic phases were combined and concentrated under reduced pressure to give 2'-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (50 mg, 107.3 µmol, 77.7% yield), as a yellow solid, which was used directly in the next step.

[0252] Compound 145: 1,1-Difluoro-2-(trifluoromethanesulfonyloxy)ethane (34.5 mg, 1.5 equivalents, 161 µmol), N-ethylbis(isopropyl)amine (53.2 µL, 3 equivalents, 322 µmol), and cesium fluoride (48.9 mg, 3 equivalents, 322 µmol) were added to a solution of 2'-((2-chloro-5,6,7,8-tetrahydropyridino[4,3-d]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (50 mg, 1 equivalent, 107 µmol) in dimethyl sulfoxide (1 mL) at 25 °C. After heating to 60°C, the mixture was stirred at 60°C for 3 h and monitored by LCMS. The mixture was quenched with water (2 mL) and extracted with ethyl acetate (2 mL × 3). The organic phases were combined and concentrated under reduced pressure to give the residue, which was then purified by preparative HPLC (column: Phenomenex Luna C18 100 x 30 mm x 3 μm; mobile phase: [A: water (0.2% formic acid); B: acetonitrile]; B%: 10.00%–45.00%, 8.00 min; flow rate: 25.00 mL / min) to give 2'-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (5.0 mg, 9.19 μL). µmol (yield 8.56%), as a yellow solid.

[0253] The compounds in Table S-2 were synthesized using general procedure B. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0254] Table S-2.

[0255] Example 10 – General Procedure C: Synthesis of (S)-2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one and (R)-2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compounds 177 and 178).

[0256] Example 3_1: 1-Fluoro-2-hydroxy-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (0.1 g, 1 equivalent, 348 µmol) was added to a solution of dimethyl sulfoxide (1 mL) at 25 °C, along with 2-chloro-4-iodo-5-((2,2,2-trifluoroethoxy)methyl)pyrimidine (123 mg, 348 µmol) and cesium carbonate (227 mg, 2 equivalent, 696 µmol). The reaction mixture was stirred at 25 °C for 1 h and monitored by LCMS. The reaction mixture was purified directly by preparative HPLC (column: Waters Xbridge BEH C18 100 * 30 mm * 10 μm; mobile phase: [A: H2O (10 mM NH4HCO3); B: ACN]; B%: 40.00%-70.00%, 8.00 min; flow rate: 25.00 ml / min) to give 2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (25 mg, 48.8 µmol, 14% yield), as a white solid.

[0257] Compounds 177 and 178: separated by SFC (column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 μm); mobile phase: [A: CO2; B: EtOH (0.1% NH3H2O)]; B%: 40.00% - 40.00%, 16.00 min; flow rate: 70.00 Separate 2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (13.9 mg, 27 µmol, 34% yield) as a white solid. (R)-2-((2-chloro-5-((2,2,2-trifluoroethoxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-10-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (15.5 mg, 30.2 µmol, 30% yield), as a white solid.

[0258] The compounds in Table S-3 were synthesized using standard procedure C. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0259] Table S-3.

[0260] Example 11: General Procedure D: An alternative procedure for the synthesis of 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 5).

[0261] Example 4_1: To a solution of 2-chloro-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid tert-butyl ester (10 g, 25.5 mmol) and 2-chloropyrimidin-4-amine (3.97 g, 30.6 mmol) in 1,4-dioxane (200 mL) under nitrogen atmosphere at 25 °C, cesium dicarbonate (24.9 g, 76.6 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethyl-9H-xanthones (2.95 g, 5.1 mmol) were added. (1E,4E)-1,5-diphenyl-1,4-pentadien-3-one-1,5-diphenyl-1,4-pentadien-3-one-palladium (1 / 2 / 2) (2.34 g, 2.55 mmol). The mixture was stirred at 100 °C for 12 h under a nitrogen atmosphere. The mixture was then monitored by LCMS. The mixture was quenched by adding water (200 mL) and extracted with ethyl acetate (3 × 200 mL). The organic phase was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give tert-butyl 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid (20 g, 41.2 mmol, 56% yield). The crude product was used in the next step without further purification.

[0262] Compound 5: 20 g (41.2 mmol) of tert-butyl 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-8H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-8-carboxylic acid was added to a solution of 2-(210 mL)-1-fluoro-7-oxo-5,6,7,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one was added at 25 °C. The reaction was stirred at 25 °C for 1 h. The reaction was then monitored by LCMS. The mixture was concentrated under reduced pressure to give the residue, which was purified by preparative HPLC (TFA) to give 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one as a yellow solid. 1¹H NMR revealed the presence of residual TFA internally. After neutralization with saturated NaHCO3 (aqueous solution), the product was purified by preparative HPLC (FA) to give 2-((2-chloropyrimidin-4-yl)amino)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (590 mg, yield 3.61%) as a yellow solid.

[0263] The compounds in Table S-4 were synthesized using standard procedure D. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0264] Table S-4. Example 12: General Procedure E: Synthesis of 2'-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (compound 181).

[0265] Example 5_1: N-ethylbis(isopropyl)amine (136 mg, 1.05 mmol) was added to a solution of 2'-amino-1'-fluoro-11'-((2-(trimethylsilyl)ethoxy)methyl)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (150 mg, 350 µmol) and 1055_3 (165 mg, 0.7 mmol) in 1,4-dioxane (3 mL) at 25 °C. The reaction was stirred at 100 °C for 12 h under a N2 atmosphere. TLC (ethyl acetate, f: material = 0.5, Rf: P1 = 0.12) showed that the starting spot was consumed and a new spot was formed. The mixture was poured into water (20 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were washed with brine (3 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under pressure to give the residue. The residue was purified by silica gel column chromatography (eluting with petroleum ether:ethyl acetate = 100:0 to 10:1) to give 2'-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-11'-((2-(trimethylsilyl)ethoxy)methyl)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (0.1 g, yield 22.78%), as a yellow solid.

[0266] Compound 181: Sodium bicarbonate (159 mg, 1.9 mmol) was added to a solution of 2'-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-11'-((2-(trimethylsilyl)ethoxy)methyl)-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (50 mg, 94.9 µmol) in dichloromethane (2.5 mL) at 25 °C, and the reaction was stirred at 25 °C for 0.5 h. The reaction was then monitored by LCMS. The mixture was filtered to remove water and purified by preparative HPLC to give 2'-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1'-fluoro-6',8',9',11'-tetrahydrospiro[cyclopropane-1,10'-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (8.5 mg, yield 3.7%) as a yellow solid.

[0267] The compounds in Table S-5 were synthesized using standard procedure E. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0268] Table S-5.

[0269] Example 13 – General Procedure F: Synthesis of 2-((2,5-dichloropyridin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 43).

[0270] Compound 43: 3-Fluoro-4-hydroxy-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16Heptadec-1(10),2(7),3,5,11(16)-pentaen-12-one (0.2 g, 1 equivalent, 732 µmol) and 4-bromo-2,5-dichloropyridine (166 mg, 1 equivalent, 732 µmol) in a solution of dimethylacetamide (3 mL) were added under N2 with (Bu4NCuI)2 (164 mg, 0.2 equivalent, 146 µmol), Me4-phenanthroline (17.3 mg, 0.1 equivalent, 73.2 µmol) and cesium carbonate (477 mg, 2 equivalent, 1.46 mmol). The reaction mixture was stirred at 120 °C for 12 h and analyzed by LCMS. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give the residue, which was purified by preparative HPLC (column: Waters xbridge 150*25 mm 10 μm; mobile phase: [A: H2O (10 mM NH4HCO3); B: ACN]; B%: 40.00%-70.00%, 9.00 min; flow rate: 25.00 ml / min) to give 4-(2,5-dichloro-4-pyridinyloxy)-3-fluoro-5,13,17-triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [16-Pentene-1(10),2(7),3,5,11(16)-one (34 mg, 81.1 µmol, 11% yield)] is a yellow solid.

[0271] Table S-6.

[0272] Example 14: General Procedure G: Synthesis of 2-((2-chloro-5-((prop-2-yn-1-yloxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 158).

[0273] Compound 158: To a solution of 2-chloro-4-iodo-5-((prop-2-yn-1-yloxy)methyl)pyrimidine (0.5 g, 1 equivalent, 1.62 mmol) in dimethyl sulfoxide (5 mL), 1-fluoro-2-hydroxy-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (443 mg, 1 equivalent, 1.62 mmol) and cesium dicarbonate (1.06 g, 2 equivalent, 3.24 mmol) were added at 25 °C. The reaction mixture was stirred at 25 °C for 2 h and monitored by LCMS. The solution was purified directly by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: [A: H2O (10 mM NH4HCO3); B: ACN]; B%: 20.00%-55.00%, 8.00 min) to obtain 2-((2-chloro-5-(((prop-2-yn-1-yloxy)methyl)pyrimidin-4-yl)oxy)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (35.9 mg, 77.3 µmol, 4% yield), as a white solid.

[0274] The compounds in Table S-7 were synthesized using standard procedure G. In some cases, Other diketone connectors such as Alternative. In some cases, Other connectors such as Alternatives. In some cases, compounds are prepared using intermediates and procedures similar to those in, for example, U.S. Patent No. 10,138,256 and U.S. Patent Application Publication No. 2016 / 0075720, each of which is incorporated herein by reference in its entirety.

[0275] Table S-7.

[0276] Example 15: Synthesis of 2'-((2-chloropyrimidin-4-yl)amino)-1'-fluoro-1-methyl-6',8',9',11'-tetrahydrospiro[azacyclobutane-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline]-7'(5'H)-one (compound 23) by using a single synthetic procedure H1.

[0277] Example 8_1: 4'-amino-3'-fluoro-12'-oxospiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 The mixture of heptadecane[1(10),2(7),3,5,11(16)]pentane-1-tert-butyl carboxylate (0.1 g, 1 equivalent, 242 µmol), 2,4-dichloropyrimidine (43.2 mg, 1.2 equivalent, 290 µmol), sodium 2-methyl-2-propoxide (46.5 mg, 2 equivalent, 484 µmol), and XantPhos Pd G4 (23.3 mg, 0.1 equivalent, 24.2 µmol) in 1,4-dioxane (6 mL) was degassed and purged three times with nitrogen. The mixture was heated to 90 °C and stirred at 90 °C for 12 h under a nitrogen atmosphere, and then monitored by TLC. Nine additional vials were prepared as described above. All ten reaction mixtures were combined and diluted with water (100 mL), extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with brine (50 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the residue, which was then analyzed by TLC (ethyl acetate = 1, R0). f =0.3) purification to obtain 4'-(2-chloro-4-pyrimidinylamino)-3'-fluoro-12'-oxospiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [1(10),2(7),3,5,11(16)]pentane]-1-carboxylic acid tert-butyl ester (270 mg, 513 µmol, 21.2% yield) is a yellow solid.

[0278] Example 8_2: To 4'-(2-chloro-4-pyrimidinylamino)-3'-fluoro-12'-oxospiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16[1(10),2(7),3,5,11(16)]pentaene]-1-carboxylic acid tert-butyl ester (270 mg, 1 equivalent, 513 µmol) in a solution of trifluoroacetic acid (3 mL). The mixture was stirred at 25 °C for 10 min and monitored by LCMS. The reaction mixture was concentrated under reduced pressure to give 4'-(2-chloro-4-pyrimidinylamino)-3'-fluorospiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 Heptadecano[1(10),2(7),3,5,11(16)]pentaene]-12'-one (200 mg, 376 µmol, 73.19% yield), a yellow oil, was used directly in the next step without further purification. LCMS: Rt: 0.298 min; [M+H] + = 426.1.

[0279] Compound 23: 4'-(2-chloro-4-pyrimidinylamino)-3'-fluorospiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0] 2 , 7 .0 11 , 16 [1(10),2(7),3,5,11(16)]pentaene]-12'-one (0.2 g, 1 equivalent, 470 µmol), formaldehyde (28.2 mg, 2 equivalent, 939 µmol), and triethylamine (143 mg, 3 equivalent, 1.41 mmol) were in a solution of methanol (10 mL) at 25 °C. After stirring at 25 °C for 30 min, sodium cyanoborohydride (88.5 mg, 3 equivalent, 1.41 mmol) was added to the mixture at 0 °C. The mixture was then heated to 25 °C and stirred at 25 °C for 30 min, and then monitored by LCMS. The reaction was concentrated under reduced pressure to give the residue, which was then purified by preparative HPLC (column: XP tC18 100 * 25 mm * 7 μm; mobile phase: [A: water (10 mM ammonium bicarbonate); B: acetonitrile]; B%: 10.00%–40.00%, 8.00 min; flow rate: 25.00 ml / min) to give 4'-(2-chloro-4-pyrimidinylamino)-3'-fluoro-1-methylspiro[azacyclobutane-3,15'-[5,13,17]triazatetracyclo[8.7.0.0]). 2 , 7 .0 11 , 16Heptadecane[1(10),2(7),3,5,11(16)]pentaene]-12'-one (53.3 mg, 121 µmol, 25.8% yield), is a white solid.

[0280] Example 16 – Synthesis of Procedure H2: Synthesis of 2-((6-chloropyrimidin-4-yl)methyl)-1-fluoro-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compound 144).

[0281] Example 9_1: Ethynyltris(methyl)silane (97.8 mL, 692 mmol) and triethylamine (144 mL, 1.04 mol), bis(triphenylphosphine)-dichloro-palladiummethane (1 / 1) (12.2 g, 17.3 mmol), and copper iodide (6.59 g, 34.6 mmol) were added to a solution of starting material (50 g, 346 mmol) in dimethylformamide (500 mL). The mixture was stirred at 50 °C for 1 h under a nitrogen atmosphere. TLC (petroleum ether:ethyl acetate = 10:1, R f = 0.5) indicates that the material was completely consumed and a new spot was formed. The reaction mixture was diluted with water (500 mL) and extracted with ethyl acetate (400 mL × 3). The combined organic layers were washed with brine (500 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by rapid silica gel chromatography (ISCO®; 220 g SepaFlash® silica gel column, eluent 0–5% ethyl acetate / petroleum ether gradient @ 200 mL / min). Example 9_1 (36 g, yield 50.45%) is given as a yellow solid.

[0282] Example 9_2: Potassium fluoride (18.2 g, 314 mmol) was added to the solution of Example 9_1 (36 g, 157 mmol) in methanol (324 mL), and the mixture was stirred at 25 °C for 1 h. TLC (petroleum ether:ethyl acetate = 10:1, R f=0.3) indicates that the material was completely consumed and a new spot was formed. The reaction mixture was concentrated under reduced pressure to remove the solvent and give the residue. The residue was extracted with water (300 mL) and ethyl acetate (300 mL × 3). The combined organic layers were washed with brine (200 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by rapid silica gel chromatography (ISCO®; 220 g SepaFlash® silica gel column, eluent 0–8% ethyl acetate / petroleum ether gradient @ 200 mL / min). Example 9_2 (19.7 g, yield 93.52%) is given as a yellow solid.

[0283] Example 9_3: Dichloro-palladiummethane-triphenylphosphine (1 / 2) (10.3 g, 14.7 mmol) and tributyltinane (43.5 mL, 162 mmol) were added to a solution of Example 9_2 (19.7 g, 147 mmol) in tetrahydrofuran (296 mL) under a nitrogen atmosphere. The mixture was stirred at 25 °C for 2 h. TLC (petroleum ether:ethyl acetate = 5:1, R f = 0.8) indicates that the material was completely consumed and a new spot was formed. The reaction mixture was extracted with water (200 mL) and ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (200 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by rapid silica gel chromatography (ISCO®; 220 g SepaFlash® silica gel column, eluent 0–8% ethyl acetate / petroleum ether gradient @ 200 mL / min). Example 9_3 (26.5 g, yield 36.07%) is given as a yellow oil.

[0284] Example 9_4: 4-chloro-3-fluoro-12-oxo-17-{[2-(trimethylsilyl)ethoxy]methyl}-5,13,17-triazatetracyclo[8.7.0.0] was added to the solution of Example 9_3 (6.5 g, 15.3 mmol) in dimethylformamide (65 mL). 2 , 7 .0 11 , 16[4 g, 7.66 mmol] tert-butyl heptadecyl-1(10),2(7),3,5,11(16)-pentane-13-carboxylate and bis(tri-tert-butylphosphonium)-palladium (1 / 1) (1.97 g, 3.83 mmol) were mixed and stirred at 100 °C for 2 h under a nitrogen atmosphere. LCMS showed that the material was consumed and a new peak with the desired mass was detected. The mixture was extracted with ethyl acetate (500 mL × 3) and water (500 mL). The combined organic layers were washed with brine (500 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the residue. The crude product was purified by preparative HPLC (FA conditions). Example 9-4 (2.6 g, yield 54.58%) is given as a yellow solid.

[0285] Example 9_5: Potassium osmium tetroxide (2-) dihydrate (474 ​​mg, 1.29 mmol) was added to a solution of Example 9_4 (4 g, 6.43 mmol) in tetrahydrofuran (40 mL) and water (40 mL) at 0 °C and stirred for 10 min. Then, sodium periodate (1-) (6.88 g, 32.2 mmol) was added to the mixture at 0 °C and stirred at 25 °C for 6 h. LCMS showed that the material was consumed and a new peak with the desired mass was detected. A saturated sodium sulfite solution (20 mL) was added to the reaction mixture and extracted with ethyl acetate (100 mL × 3). The organic matter was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under vacuum to give a crude product. The crude product was purified by preparative HPLC (FA conditions) to give Example 9_5 (1.5 g, yield 37.38%) as a brown solid.

[0286] Example 9_6: Sodium borohydride (773 mg, 20.4 mmol) was added to a solution of Example 9_5 (1.5 g, 2.4 mmol) in methanol (30 mL) at 0 °C, and the mixture was stirred at 0 °C for 1 h. LCMS showed that the material was completely consumed and a new peak with the desired mass was detected. The reaction mixture was quenched by adding saturated ammonium chloride aqueous solution (200 mL) and extracted with ethyl acetate (100 mL × 3). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give Example 9_6 (1.5 g, yield 83.73%) as a brown solid. The crude product was used directly in the next step without purification.

[0287] Example 9_7: Triethylamine (1.21 g, 12 mmol) was added to a solution of Example 9_6 (3 g, 4.79 mmol) in dichloromethane (30 mL). The mixture was cooled to 0 °C and (chlorosulfonyl)methane (730 mg, 6.37 mmol) was added. The mixture was stirred at 0 °C for 1 h. LCMS showed that the material was completely consumed and a new peak with the desired mass was detected. Water (200 mL) was added to the mixture and it was extracted with dichloromethane (100 mL × 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a residue as a brown solid. The crude product of Example 9_7 (1.7 g, yield 40.3%) was used directly in the next step without purification.

[0288] Example 9_8: Palladium (617 mg, 5.8 mmol) was added to a solution of Example 9_7 (1.7 g, 1.93 mmol) in methanol (28.9 mL), and the mixture was stirred at 25 °C for 3 h under hydrogen (15 psi). LCMS showed that the material was completely consumed and a new peak with the desired mass was detected. The reaction mixture was filtered and the filter cake was washed with methanol. The combined filtrates were then concentrated under reduced pressure to give a crude product. The residue was purified by rapid silica gel chromatography (ISCO®; 20 g SepaFlash® silica gel column, eluent 0–60% ethyl acetate / petroleum ether gradient @ 200 mL / min). Example 9_8 (750 mg, 63.66% yield) was given as a yellow solid.

[0289] Example 9_9: Lithium chloride (521 mg, 12.3 mmol) and p-toluenesulfonic acid-water (1 / 1) (2.34 g, 12.3 mmol) were added to a solution of Example 9_8 (750 mg, 1.23 mmol) in dimethylformamide (7.5 mL), and the mixture was stirred at 110 °C for 2 h. LCMS showed that the material was consumed and a new peak with the desired mass was detected. Water (10 mL) was added to the reaction mixture and extracted with ethyl acetate (10 mL × 3). The organic matter was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under vacuum to give a crude product. The residue was purified by rapid silica gel chromatography (ISCO®; 6 g SepaFlash® silica gel column, eluent 0–5% methanol / ethyl acetate @ 200 mL / min). Example 9_9 (200 mg, yield 26.25%) was given as a yellow solid.

[0290] Compound 144: N-ethylbis(isopropyl)amine (62.6 mg, 484 µmol) and phosphorus oxychloride (136 mg, 888 µmol) were added to a solution of Example 9_9 (0.2 g, 404 µmol) in 1,2-dichloroethane (1 mL), and the mixture was then stirred at 85 °C for 2 h. LCMS showed that Example 9_9 was consumed and a new peak with the mass of Example 9_10 was detected. The reaction mixture was used for the next step without purification. Trifluoroacetic acid (1 mL) was added to the reaction mixture and stirred at 25 °C for 30 min, followed by the addition of a saturated aqueous solution of sodium bicarbonate at 25 °C for 1 h. LCMS showed a new peak with the desired mass. The crude product was purified by preparative HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [A: H2O (10 mM NH4HCO3); B: ACN]; B%: 20.00%-50.00%, 8.00 min) to give compound 144 (3 mg, yield 1.94%) as a pale yellow solid.

[0291] Example 17 – Synthesis of Procedure H3: Synthesis of 2-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-11-methyl-5,6,8,9,10,11-hexahydro-7H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7-one (compounds 142 and 143).

[0292] Example 10_1: A solution of the starting material (1 g, 2.55 mmol) in DMA (10 mL, 108 mmol) was stirred at 0 °C. 60% NaH (153 mg, 1.5 equivalents, 3.83 mmol) was added and stirred at 0 °C for 0.5 h. MeI (1.81 g, 5 equivalents, 12.8 mmol) was added dropwise at 0 °C, and the reaction mixture was stirred at 0 °C for 1 h. LCMS (Rt(product) = 0.517 min, M+H = 350.1) showed that the starting material was completely consumed. The reaction mixture was quenched with NH4Cl (50 mL) for extraction and then extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine (15 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (PE: EtOAc = 1:1 to 0:1) to give compound 10_1 (820 mg, 2.02 mmol) as a yellow solid.

[0293] Example 10_2: 737_1A (1 g, 1.82 mmol), Cs₂CO₃ (1.97 g, 3 equivalents, 6.06 mmol), XantPhos (234 mg, 0.2 equivalents, 404 µmol), and Pd₂(dba)₃ (185 mg, 0.1 equivalents, 202 µmol) were added to a solution of 10_1 (820 mg, 2.02 mmol) in 1,4-dioxane (10 mL, 117 mmol) at 25 °C. The reaction mixture was stirred at 100 °C for 4 h. LCMS (Rt(product) = 0.922 min, M+H = 551.2) showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography (PE:EtOAc = 1:1 to 0:1) to give compound 10⁻² (1 g, 1.82 mmol) as a yellow oil.

[0294] Example 10_3: 5 N hydrogen chloride (688 mg, 18 equivalents, 18.9 mmol) was added to a solution of 10_2 (1 g, 1.7 equivalence, 1.82 mmol) in tetrahydrofuran (10 mL, 123 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 16 h. LCMS (Rt(product) = 0.239 min, M+H = 287.1) showed complete consumption of the starting material. The reaction mixture was extracted by quenching with NaHCO3 (15 mL) and then extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine (15 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (EtOAc: MeOH = 1:0 to 0:1) to give compound 10_3 (0.4 g, 1.4 mmol) as a yellow solid.

[0295] Compounds 142 and 143: Cs₂CO₃ (50.8 mg, 3 equivalents, 156 µmol), MTX-01-207-1 (305 mg, 2 equivalents, 1.4 mmol), XantPhos (80.8 mg, 0.2 equivalents, 140 µmol), and Pd₂(dba)₃ (64 mg, 0.1 equivalents, 69.9 µmol) were added to a solution of 737_3 (0.2 g, 699 µmol) in 1,4-dioxane (2 mL, 23.4 mmol) at 25 °C. The reaction mixture was stirred at 100 °C for 3 h. LCMS (Rt(product) = 0.299, 0.325 min, M+H = 468.2) showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (EtOAc: MeOH = 1:0 to 1:1) to give the residue. It was then further purified by preparative HPLC (neutral conditions) (column: Waters Xbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: [A: H2O (10 mMNH4HCO3); B: ACN]; B%: 15.00%–55.00%, 8.00 min). Compound 142 (8 mg, 17.1 µmol, 2.39% yield) and compound 143 (1 mg, 2.14 µmol, 0.27% yield) were given as brown solids.

[0296] Example 18 – Synthesis of Procedure H4 alone: ​​Synthesis of 2-((2-chloro-6-(2-hydroxy-2-methylpropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one. (Compound 39) Compound 39: 2-((2-chloro-6-(2-hydroxy-2-methylpropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one: (4 batches) to 2-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (20 mg, 1 equivalent, 43.2 µmol) in dimethylformamide (0.5 mL, 6.46 Potassium carbonate (17.9 mg, 3 equivalents, 130 µmol), 1-chloro-2-methyl-2-propanol (23.4 mg, 5 equivalents, 216 µmol), and sodium iodide (8.26 mg, 1.3 equivalents, 55.1 µmol) were added to a solution containing 17.9 mg (mmol) at 25 °C. The reaction mixture was stirred at 100 °C for 12 h and monitored by LCMS. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC (column: Waters Xbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: A: H2O (10 mM NH4HCO3); B: ACN, gradient: B from 10.00% to 40.00% over 8.0 min) to give 2-((2-chloro-6-(2-hydroxy-2-methylpropyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (12 mg, 22.5 µmol, 13% yield), as a yellow solid.

[0297] Example 19: Synthesis of procedure H5 alone: ​​Synthesis of 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one. (Compound 37) Compound 37: 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one: Acetone (60.7 μmol) was added to a solution of 2-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (50 mg, 1 equivalent, 105 µmol) in 1,2-dichloroethane (1 mL) at 0 °C. Sodium triacetoxyborohydride (44.3 mg, 10 equivalents, 1.05 mmol) and acetic acid (12.6 mg, 2 equivalents, 209 µmol) were added to the reaction solution at 25 °C for 1 h. The reaction mixture was stirred at 25 °C for 12 h and monitored by LCMS. The reaction mixture was diluted with water (3 mL) and extracted with dichloromethane (3 × 1 mL). The combined organic layers were washed with brine (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: WatersXbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: A: H2O (10 mM NH4HCO3); B: ACN, gradient: B from 10.00% to 45.00% over 8.00 min) to give 2-((2-chloro-6-isopropyl-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-4-yl)amino)-1-fluoro-8,9,10,11-tetrahydro-5H-pyridino[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (17 mg, 33.6 µmol, 32% yield) as a yellow solid.

[0298] Example 20: Synthesis of Procedure H6 alone: ​​Synthesis of 2-(2-((2,5-dichloropyridin-4-yl)amino)-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (compound 44) Example 13_1: 2,2-Dimethoxyethyl-1-amine (3.08 g, 1 equivalent, 29.3 mmol) was added to a solution of tert-butyl 2,4-dioxopiperidine-1-carboxylate (6.25 g, 1 equivalent, 29.3 mmol) and 4A molecular sieve (0.2 g) in toluene (62.5 mL) at 20 °C. The reaction mixture was then stirred at 70 °C for 1 h under a nitrogen atmosphere and monitored by TLC. Three additional vials were prepared as described above. All four suspensions were combined and diluted with ethyl acetate (500 mL), washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give crude (Z)-4-((2,2-dimethoxyethyl)imino)-2-oxopiperidine-1-carboxylate (30 g, 0.1 mol, 85% yield) as a yellow solid, which was used directly in the next step without further purification.

[0299] Example 13_2: Trifluoroacetic acid (100 mL) was added to a solution of (Z)-4-((2,2-dimethoxyethyl)imino)-2-oxopiperidin-1-carboxylic acid tert-butyl ester (30 g, 1 equivalent, 99.9 mmol) in dichloromethane (71 mL) at 0 °C. The reaction mixture was then stirred at 25 °C for 3 h and monitored by TLC. The suspension was concentrated under reduced pressure to give the residue, which was purified by silica gel chromatography (eluting with 5% methanol in ethyl acetate). The purified fractions were combined and concentrated to give 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (12 g, 88.1 mmol, 88% yield) as a white solid.

[0300] Example 13_3: 4,4,5,5-Tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (5 g, 1 equivalent, 36.2 mmol) was added to a solution of 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (5 g, 1 equivalent, 36.2 mmol) in toluene (50 mL) and tetrahydrofuran (50 mL) at 25°C under a nitrogen atmosphere. This was followed by the addition of 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1,3,2-dioxaborhexacyclopentane (18.4 g, 2 equivalents, 72.4 mmol) and [Ir(OCH3)(C8H 12 )]2 (1.31 g, 0.05 equivalent, 1.81 mmol) and pentacyclic [10.6.2.0] 2 , 7 .0 9 , 19 .0 16 , 20[1.04 g, 0.1 equivalent, 3.62 mmol] Eicos-1(19),2(7),3,8,10,12(20),13,15,17-nonen-5,6-diol (0.1 g, 0.1 equivalent, 3.62 mmol). The reaction mixture was then stirred at 100 °C for 16 h under a nitrogen atmosphere and monitored by TLC. An additional vial was prepared as described above. The two reaction mixtures were combined and concentrated to the residue under reduced pressure, which was purified by silica gel column chromatography (eluting with ethyl acetate) to obtain 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (9.2 g, 34.9 mmol, 41% yield) as a grayish-white solid.

[0301] Example 13_4: 4-Bromo-3-fluoro-2-pyridinium (802 mg, 1.1 equivalent, 4.2 mmol), dipotassium carbonate (1.58 g, 3 equivalent, 11.4 mmol), and 1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (312 mg, 0.1 equivalent, 382 µmol) were added to a solution of 2-(4,4,5,5-tetramethyl-1,3,2-dioxolane-2-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (1 g, 1.1 equivalent, 3.82 mmol) in 1,4-dioxane (20 mL) and water (5 mL) at 25 °C under nitrogen atmosphere. The two reaction mixtures were combined, quenched with water (50 mL), and extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with brine (2 × 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the residue, which was purified by preparative HPLC (column: Phenomenex Luna C18 80*30 mm*3 μm, mobile phase: A: H2O (0.2% FA); B: acetonitrile, gradient: B: 1.00% to 25.00% over 8.00 min) to obtain 2-(2-amino-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (0.2 g, 809 µmol, 10% yield) as a yellow solid.

[0302] Compound 44: 4-Bromo-2,5-dichloropyridine (111 mg, 0.8 equivalent, 487 µmol), cesium dicarbonate (298 mg, 1.5 equivalent, 914 µmol), 4,5-bis(diphenylphosphino)-9,9-dimethyl-9H-xanthones (17.6 mg, 0.05 equivalent, 30.5 µmol), and (1E,4E)-1,5-diphenyl-1,4-pentadien-3-one-1,5-diphenyl-1,4-pentadien-3-one-palladium (1 / 2 / 2) were added to a solution of 2-(2-amino-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (150 mg, 1 equivalent, 609 µmol) in toluene (15 mL) under nitrogen atmosphere at 25 °C. (27.9 mg, 0.05 equivalent, 30.5 µmol). The reaction mixture was then stirred at 140 °C for 16 h under a nitrogen atmosphere and monitored by LCMS. The reaction mixture was concentrated under reduced pressure to give the residue, which was purified by preparative HPLC (column: Waters Xbridge PrepOBD C18 150*40 mm*10 μm, mobile phase: A: H2O (10 mM NH4HCO3); B: acetonitrile, gradient: B: 40.00% to 75.00% over 8.00 min) to obtain 2-(2-((2,5-dichloropyridin-4-yl)amino)-3-fluoropyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one (82.3 mg, 20.9 µmol, 33% yield) as a white solid.

[0303] Example 21: Synthesis of 2-((6-chloropyridazin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (compound 65) by using a single synthetic procedure H7.

[0304] Compound 65: Sodium hydride (293 mg, 4 equivalents, 7.32 mmol, 60% purity) was added to a solution of 1-fluoro-2-hydroxy-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (0.5 g, 1 equivalent, 1.83 mmol) in dimethylformamide (10 mL) at 0 °C under N2. The reaction mixture was stirred at 0 °C for 0.5 h. Then, 3,5-dichloropyridazine (545 mg, 2 equivalents, 3.66 mmol) was added to the above reaction solution at 0 °C. The reaction mixture was stirred at 110 °C for 12 h and monitored by LCMS. The reaction mixture was quenched by adding saturated NH4Cl (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting with petroleum ether:ethyl acetate = 1:1 to 0:1) to give 2-((6-chloropyridazin-4-yl)oxy)-1-fluoro-8,9,10,11-tetrahydro-5H-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinoline-7(6H)-one (2.3 mg, 6.12 μmol, 0.3% yield) as a pale yellow solid.

[0305] Table S-8.

[0306] Biological Examples The following describes exemplary assays for evaluating the bioactivity of the compounds described herein.

[0307] Example B-1 - Biochemical Assay of MK2 MK2 kinase activity was monitored using the ADP-Glo™ kinase assay by measuring its effect on MK2 phosphorylation of the peptide substrate HSP27tide (RRLNRQLSVA-amide). Kinase reactions were performed in 384-well, low-friction, white, flat-bottomed polystyrene non-binding surface plates. MK2 was diluted to 0.625 nM in BSA-containing assay buffer (40 mM Tris pH 7.5, 20 mM MgCl2, 0.125 mg / ml BSA, 0.5 mM TCEP), and 6 µL was added to each well. Subsequently, the test compound dissolved in DMSO or DMSO alone (as a control) was diluted to 5% DMSO in BSA-free assay buffer (40 mM Tris pH 7.5, 20 mM MgCl2, 0.5 mM TCEP), and 3 µL of aliquot was added to each well. The plates were incubated at room temperature for 1 hour. The reaction was initiated by adding 3 µL of 50 µM ATP and 3 µL of 1 mg / mL substrate. The plate was incubated on a shaker at 300 rpm at room temperature for 1 hour. The reaction was terminated by depleting the remaining ATP by adding 15 µL of ADP-Glo™ reagent to each well. The plate was incubated at room temperature for 40 minutes. Finally, 30 µL of kinase assay reagent was added to each well, and the plate was incubated at room temperature for another 30 minutes. The luminescence of each well was measured using an EnVision® (PerkinElmer) microscope.

[0308] The above procedure was performed on the compounds in Table B-1, and the results are provided. The symbol "++++" indicates IC. 50 Less than or equal to 10 nM. The symbol "++" indicates IC. 50 Greater than 10 nM and less than or equal to 100 nM. The symbol "++" indicates IC. 50 Greater than 100 nM and less than or equal to 1000 nM. The symbol "+" indicates the IC. 50 Greater than 1000 nM.

[0309] Table B-1.

[0310] Example B-2 - HeLa Cell HSP27 S78 Phosphorylation Assay Phosphorylated HSP27 ELISA and total HSP27 ELISA were performed using the PathScan® Phosphorylated HSP27 (Ser78) Sandwich ELISA Kit (Cell Signaling: 7290) and the PathScan® Total HSP27 Sandwich ELISA Kit (Cell Signaling: 7295), respectively. HeLa cells (ATCC: CCL-2) were cultured in DMEM medium containing 10% heat-inactivated fetal bovine serum and 100 U / mL penicillin-streptomycin at 37°C and 5% CO2. The day before the assay, HeLa cells were sputtered at 0.25 × 10⁶ cells / mL. 5 Cells were seeded per well in 96-well plates. The following day, cells were incubated with the test compound in culture medium at 37°C (100 µL / well). After 1 hour of incubation, cells were treated with IL-1b (10 ng / mL) at 37°C for 20 minutes (200 µL / well). After incubation, cells were washed with PBS 1x and lysed with 200 µL of lysis buffer (from the ELISA kit) containing a mixture of phosphatase inhibitors added to each well, and incubated on ice for 5 minutes. Subsequently, the cell lysates were centrifuged at 4°C for 10 minutes (x3,000 g). The presence of phosphorylated HSP27 (S78) and total HSP27 in the supernatant samples was determined by ELISA.

[0311] Example B-3 - TNF-α Release Assay in PBMCs (Peripheral Blood Mononuclear Cells) TNF-α ELISA was performed using a human TNF-α ELISA kit (Abcam: ab181421). PBMCs were cultured in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 100 U / mL penicillin-streptomycin at 37°C and 5% CO2. PBMCs were then cultured at 1×10⁻⁶... 5 Cells were seeded in 96-well plates and incubated with the test compound in culture medium at 37°C (100 µL / well). After 3 hours of incubation, cells were treated with lipopolysaccharide (LPS, 100 ng / ml) at 37°C for 4 hours (200 µL / well). Following incubation, the presence of TNF-α in the supernatant samples was determined by ELISA.

[0312] The above procedure was performed on the compounds in Table B-2, and the results are provided. The symbol "++++" indicates IC. 50 Less than or equal to 10 nM. The symbol "++" indicates IC. 50 Greater than 10 nM and less than or equal to 100 nM. The symbol "++" indicates IC. 50 Greater than 100 nM and less than or equal to 1000 nM. The symbol "+" indicates the IC.50 Greater than 1000 nM.

[0313] Table B-2.

[0314] All publications, patent applications, patents and other references mentioned in this article are explicitly incorporated in their entirety by reference, to the same extent that each publication, patent application, patent and other reference is incorporated by reference individually.

Claims

1. A compound of formula (I), (I), Or its stereoisomers or tautomers, or pharmaceutically acceptable salts of any of the foregoing, wherein L is -C(R) 17 (R) 18 -, -C(O)-, -O-, -NR 10 -or -S(O) n -; R 1 and R 2 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 2-4 Halogenated alkynyl groups, in which The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 or -N(R) 10 (R) 10 Replace; or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 4-6 membered heterocyclic group, wherein the C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 2a replace; R 3 and R 4 H, D, C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 Halogenated alkyne groups are independently and optionally -OR 10 -N(R) 10 (R) 10 C 3-6 Cycloalkyl or 4-6 membered heterocyclic substituted, and R 3 and R 4 The C mentioned 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are optionally separated by one or more R 4a Replace; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, wherein the C 3-6 cycloalkyl or the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace; R 5 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 6 It is H, C 1-2 Alkyl, C 1-2 Halogenated alkyl or C 3-5 cycloalkyl; R 7 It is a 5-6 membered heteroaryl or a partially unsaturated 8-14 membered heterocyclic group, among which The carbon atom adjacent to the heteroatom on the 5-6 membered heteroaryl group or the 8-14 membered heterocyclic group is R 8 replace, The 5-6 quinone heteroaryl group is optionally further divided by one or more R groups. 9 Replace, and The 8-14 membered heterocyclic group may optionally be further substituted by one or more substituents selected from the group consisting of: oxo and R. 9 ; R 8 It is halogenated or -S(O) n (R 13 ); Each R 9 Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkyne group, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -OC(O)-R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic, phenyl, or 5-6 membered heteroaryl, wherein The C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 2-4 alkenyl, the C 2-4 Haloalkenyl, the C 2-4 alkynyl group and the C 2-4 The halogenated alkynyl group is independently and optionally surrounded by one or more R groups. 9a replace; The C 3-6 The cycloalkyl group and the 4-6 membered heterocyclic group are independently and optionally separated by one or more R groups. 9b Replace; and The phenyl group and the 5-6-membered heteroaryl group are each optionally and independently converted by one or more R groups. 9c replace; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 membered heteroaryl, among which, The C 3-6 cycloalkyl groups are optionally surrounded by one or more R 14 Replace, and The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ; Each R 9b Independently, it is halogenated, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl, C 1-4 Halogenated alkyl or oxoalkyl; or Each R 9c Independently, it is halogenated, -CN, -OR 10 -N(R) 10 (R) 10 C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 10 H and C independently 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 alkenyl, C 1-4 alkynyl group, C 3-4 cycloalkyl or 3-8 membered heterocyclic groups; Wherein C 1-4 Alkyl, the C 1-4 Halogenated alkyl groups, the C 1-4 alkenyl or the C 1-4 The alkynyl group is optionally surrounded by one or more R 10a Replace, and The C 3-4 cycloalkyl or the 3-8 membered heterocyclic group is optionally surrounded by one or more R 10b Replace; and Each R 10a Independently, it is D, -OR 14 Or C 3-4 cycloalkyl; Each R 2a R 4a and R 10b Independently, it is halogenated, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkyl-(OR) 14 C 1-4 Halogenated alkyl-(OR) 14 -OR 14 or -N(R) 14 (R) 14 ); X is N or CR 11 ; R 11 It is H, halogenated, C 1-4 Alkyl, C 1-4 Halogenated alkyl groups or -CN; Each R 12 C is independent 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl group, C 2-4 Halogenated alkynyl group, C 3-6 cycloalkyl, -OR 14 -N(R) 14 (R) 14 ) or 3-8 membered heterocyclic groups, among which The 3-8 membered heterocyclic group is optionally halogenated, C 1-4 Alkyl or C 1-4 Halogenated alkyl substitution; R 13 It is C 1-4 Alkyl or C 1-4 Halogenated alkyl groups; Each R 14 H and C independently 1-4 Alkyl, C 1-4 Halogenated alkyl or C 3-6 cycloalkyl; n is 0, 1, or 2 independently each time it appears; Indicates a single key or a double key, where when When it is a single bond, p and q are both 2, and when When it is a double bond, p and q are both 1; Each R 15 and R 16 Independently, it is H, D, or C. 1-4 alkyl; R 17 It is H, -CH3, -CF3, halogenated, or -OH; and R 18 It is H, -CH3, -CF3, or halogenated. Or R 17 and R 18 Together with the carbon atoms to which they are attached, they form cyclopropyl groups. The condition is that when L is -O-, R 1 -R 6 Each of them is H, R 7 It is 2-chloropyrimidin-4-yl, X is CF. It is a single bond, and each R 15 and R 16 When it is H, then R 9 It is not ethoxymethyl.

2. The compound according to claim 1, wherein... R 5 Is it H or C? 1-2 alkyl; R 6 Is it H or C? 1-2 alkyl; Each R 9a Independently, they are D, -CN, -OR 10 -N(R) 10 (R) 10 ), -N(R 10 )-C(O)-R 12 -N(R) 10 )-S(O) n -(R 12 -C(O)-R 12 -S(O) n (R 12 C 3-6 Cycloalkyl, 4-10 membered heterocyclic groups, C 6-10 Aryl or 5-6 quinone heteroaryl, among which The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated, and R-substituted groups. 14 ;and Each R 4a It is C 1-4 alkyl.

3. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ia-1), (Ia-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

4. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ia-2), (Ia-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is -C(R 17 (R) 18 )- or -C(O)-.

5. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ib-1), (Ib-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

6. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ib-2), (Ib-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

7. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ic-1), (Ic-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

8. The compound according to claim 1 or 2, wherein the compound is a compound of formula (Ic-2), (Ic-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

9. The compound according to claim 1 or 2, wherein the compound is a compound of formula (1d-1), (Id-1), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

10. The compound according to claim 1 or 2, wherein the compound is a compound of formula (1d-2). (Id-2), or its stereoisomers or tautomers, or a pharmaceutically acceptable salt of any of the foregoing.

11. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein L is -C(R) 17 (R) 18 -, -O-, or -NR 10 - 12. The compound according to any one of claims 1-4 or 11, or a pharmaceutically acceptable salt thereof, wherein L is -CH2-, -CHF-, -CF2-, -O-, -N(H)-, or -N(C 1-4 alkyl)-.

13. The compound according to any one of claims 1-4, 11 or 12, or a pharmaceutically acceptable salt thereof, wherein in some embodiments, L is -O-, -N(H)- or -N(C)-. 1-4 alkyl)-.

14. The compound according to any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group is optionally surrounded by one or more R 2a replace.

15. The compound according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 4-6-membered heterocyclic group, wherein the 4-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution.

16. The compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's H, or R 1 and R 2 Together with the carbon atoms to which they are attached, they form cyclopropyl or N-methylazacyclobutane groups.

17. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Each is H.

18. The compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6 membered heterocyclic group, wherein the 3-6 membered heterocyclic group is optionally surrounded by one or more R 4a replace.

19. The compound according to any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 H and C independently 1-4 Alkyl or C 1-4 Halogenated alkyl, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form C 3-6 Cycloalkyl or 3-6-membered heterocyclic group, wherein the 3-6-membered heterocyclic group is optionally C 1-4 Alkyl substitution.

20. The compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 Independently, it is H, -CH3, or -CF3, or R 3 and R 4 Together with the carbon atoms to which they are attached, they form cyclopropyl, cyclobutyl, or N-methylazacyclobutane groups.

21. The compound according to any one of claims 1 or 3-20, or a pharmaceutically acceptable salt thereof, wherein R 5 It is H, C 1-2 Alkyl or C 1-2 Halogenated alkyl groups.

22. The compound according to any one of claims 1 or 3-21, or a pharmaceutically acceptable salt thereof, wherein R 5 It is H, -CH3, -CH2CH3, -CH2CF3 or -CH2CF2H.

23. The compound according to any one of claims 1 or 3-22, or a pharmaceutically acceptable salt thereof, wherein R 6 It is H, C 1-2 Alkyl or C 1-2 Halogenated alkyl groups.

24. The compound according to any one of claims 1 or 3-23, or a pharmaceutically acceptable salt thereof, wherein R 6 It is H, -CH3, -CH2CH3, -CH2CF3 or -CH2CF2H.

25. The compound according to any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 Each is H.

26. The compound according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R 1 R 2 R 5 and R 6 Each is H.

27. The compound according to any one of claims 1-26, or a pharmaceutically acceptable salt thereof, wherein R 1 R 2 R 3 R 4 R 5 and R 6 Each is H.

28. The compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 5-6 aryl groups.

29. The compound according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 5-membered heteroaryl group.

30. The compound according to any one of claims 1-29, wherein R 7 It is a pyrazolyl, oxazolyl, or thiazolyl group, wherein the pyrazolyl, oxazolyl, or thiazolyl group is R 8 Replaced and optionally by one or more R 9 replace.

31. The compound according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 6-membered heteroaryl group.

32. The compound according to any one of claims 1-28 or 31, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted pyrimidine group.

33. The compound according to any one of claims 1-28 or 31, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a pyridinyl group, wherein the pyridinyl group is R 8 Replaced and optionally by one or more R 9 replace.

34. The compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 It was R 8 Replaced and optionally by one or more R 9 Substituted 8-14 membered heterocyclic groups.

35. The compound according to any one of claims 1-27 or 34, or a pharmaceutically acceptable salt thereof, wherein R 7 It is 5,6,7,8-tetrahydropyrido[4,3- d ]pyrimidinyl, wherein the 5,6,7,8-tetrahydropyridyl[4,3- d Pyrimidine is R 8 Replaced and optionally by one or more R 9 replace.

36. The compound according to any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein R 8 It is halogenated.

37. The compound according to any one of claims 1-36, or a pharmaceutically acceptable salt thereof, wherein R 8 It is Cl or F.

38. The compound according to any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein R 8 It is Cl.

39. The compound according to any one of claims 1-38, or a pharmaceutically acceptable salt thereof, wherein R 9 It is optionally controlled by one or more R 9a Replacement C 1-4 alkyl.

40. The compound according to any one of claims 1-39, wherein R 9a It is -CN, -OR 10 -C(O)-R 12 -S(O)2-(R 12 C 3-6 Cycloalkyl or 4-10 membered heterocyclic groups, The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated and -CH3.

41. The compound according to any one of claims 1-40, wherein R 9a It is -CN, -OH, -O(C) 1-4 Alkyl), -O(C) 1-4 Halogenated alkyl), -O(C) 3-6 cycloalkyl), -O (4-6 membered heterocyclic groups), -C(O)-(C 3-6 cycloalkyl), -C(O)-[N(C 1-4 Alkyl)(C 1-4 Alkyl)]、-S(O)2-(C 1-4 Alkyl), -S(O)2-N(C 1-4 Alkyl)(C 1-4 Alkyl), C 3-6 Cycloalkyl or 4-10 membered heterocyclic groups, The 4-10 membered heterocyclic group is optionally substituted by one or more substituents selected from the group consisting of: oxo, halogenated and -CH3.

42. The compound according to any one of claims 1-41, wherein R 9a The following groups are selected: pyrrolidinyl, piperidinyl, piperazineyl, morpholino, isothiazolyl and 5-azaspiro[2.4]heptyl.

43. The compound according to any one of claims 1-39, wherein R 9 It is C 1-4 alkyl.

44. The compound according to any one of claims 1-39 or 43, wherein R 9 It is -CH3.

45. The compound according to any one of claims 1-38, or a pharmaceutically acceptable salt thereof, wherein R 9 It is optionally controlled by one or more R 9b Replacement C 3-6 Cycloalkyl.

46. ​​The compound according to any one of claims 1-38 or 45, or a pharmaceutically acceptable salt thereof, wherein R 9 It is cyclopropyl.

47. The compound according to any one of claims 1-29, 32 or 33, wherein R 7 yes .

48. The compound according to any one of claims 1-27 or 34-38, wherein R 7 It can be arbitrarily divided by 1, 2 or 3 Rs 9 Group substitution .

49. The compound according to any one of claims 1-27 or 34-38, wherein R 7 It can be arbitrarily divided by 1 or 2 Rs 9 Group substitution .

50. The compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein R 7 Choose from the following groups: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .

51. The compound according to any one of claims 1, 2, 4, 6, 8 or 10-50, or a pharmaceutically acceptable salt thereof, wherein X is a CR 11 .

52. The compound of claim 51, or a pharmaceutically acceptable salt thereof, wherein R 11 It is H or halogenated.

53. The compound according to claim 51 or 52, or a pharmaceutically acceptable salt thereof, wherein R 11 It is H or F.

54. The compound according to any one of claims 1-3, 5, 7, 9, 11 or 11-50, or a pharmaceutically acceptable salt thereof, wherein X is N.

55. A compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, is selected from compounds 1-32 and 34-189 of Table 1.

56. A compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, is selected from compounds 1-32 and 34-141 of Table 1.

57. A pharmaceutical composition comprising a compound according to any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

58. A method for treating a disease or condition mediated by MK2, the method comprising administering to a subject in need a compound according to any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 57.

59. The method of claim 58, wherein a therapeutically effective amount of the compound is administered.

60. The method of claim 58 or 59, wherein the disease or condition mediated by MK2 is an inflammatory disorder.

61. The method according to claim 58 or 59, wherein the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, celiac disease, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjögren's syndrome, scleroderma, ulcerative colitis, asthma, uveitis, psoriatic arthritis, hidradenitis suppurativa, cryopyridine-associated periodic syndrome, or juvenile idiopathic arthritis.

62. The method according to claim 58 or 59, wherein the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, celiac disease, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjögren's syndrome, scleroderma, ulcerative colitis, or asthma.

63. The method according to claim 58 or 59, wherein the disease or condition mediated by MK2 is rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, cryopyridine-associated periodic syndrome, or juvenile idiopathic arthritis.

64. The method according to claim 58 or 59, wherein the disease or condition mediated by MK2 is selected from the following cancers: pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal carcinoma, skin cancer, bladder cancer, prostate cancer, head and neck cancer, or glioblastoma.

65. The method of claim 58 or 59, wherein the disease or condition mediated by MK2 is pancreatic cancer.

66. The method of claim 58 or 59, wherein the disease or condition mediated by MK2 is a fibrotic disease.

67. The method of claim 66, wherein the fibrotic disease is idiopathic pulmonary fibrosis.

68. The method according to any one of claims 58-67, wherein the subject is a human.

69. A method for inhibiting MK2 activity, the method comprising contacting MK2 with an effective amount of the compound according to any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

70. A method for covalently modifying MK2, the method comprising contacting MK2 with an effective amount of the compound according to any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

71. A covalently modified MK2, formed by the method according to claim 70.

72. The compound of any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 57, for use in the treatment of MK2-mediated diseases or disorders.

73. Use of the compound, stereoisomer or tautomer thereof, pharmaceutically acceptable salt thereof, or pharmaceutical composition according to claim 57 in the manufacture of a medicament for treating diseases or disorders mediated by MK2.

74. A kit comprising: (i) a compound according to any one of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 57, and (ii) instructions for use in treating MK2-mediated diseases or conditions in individuals in need.

Citation Information

Patent Citations

  • MK2 inhibitors and uses thereof

    US10138256B2

  • MK2 inhibitors and uses thereof

    US11098061B2

  • MK2 inhibitors and uses thereof

    US20160075720A1

  • Methods of treating a MK2-mediated disorder

    US20220251105A1

  • Methods of treating acute respiratory disorders

    US20230255979A1